Use of bcmap329g antibody and car-t cell in treatment of multiple myeloma

Through the combination of P329G mutant antibodies and CAR-T cells, BCMA-specific antibodies are used as molecular switches to regulate CAR-T cell activity, solving the problems of toxicity and recurrence of traditional CAR-T cell therapy, and achieving a safer and longer-lasting Anti-tumor effects and lower treatment costs.

WO2024230776A1PCT designated stage expired Publication Date: 2024-11-14INNOVENT CELLS PHARM (SU ZHOU) CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/091965
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-10
Filing Date
2024-05-09
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Traditional CAR-T cell therapy has toxicity and recurrence problems in the treatment of multiple myeloma, especially the toxicity and tumor resistance of "target/detumor" and it is difficult to effectively control the activity and survival of CAR-T cells, which affects the long-term Treatment effect.

Method used

A therapy was designed to combine P329G mutant antibodies with CAR-T cells, using BCMA-specific P329G antibodies as a "molecular switch" to regulate the activity of CAR-T cells, and regulate CAR-T through the frequency, dose and pathway of antibody administration. Cell recognition and killing effects, avoid toxic side effects, and overcome drug resistance and recurrence problems.

Benefits of technology

Effectively reduce the acute toxic side effects in CAR-T cell therapy, promote continuous amplification and survival in the body, improve anti-tumor effect, prolong the treatment durability, reduce the treatment cost, improve the accessibility of treatment and Security.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2024091965-FTAPPB-I100001
    Figure PCTCN2024091965-FTAPPB-I100001
  • Figure PCTCN2024091965-FTAPPB-I100002
    Figure PCTCN2024091965-FTAPPB-I100002
  • Figure PCTCN2024091965-FTAPPB-I100003
    Figure PCTCN2024091965-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention relates to a use of a drug combination for treating a BCMA-related disease in a subject.
Need to check novelty before this filing date? Find Prior Art

Description

Application of BCMAP329G antibody and CAR-T cells in the treatment of multiple myeloma

[0001] This application is based on the Chinese patent application with application number 202310524366.8 and application date May 10, 2023, and claims the priority of the Chinese patent application. The entire content of the Chinese patent application is hereby introduced into this application as a reference. Technical Field

[0002] The present invention generally relates to the fields of antibody engineering and cellular immunology. In particular, the present invention relates to a combination of an antibody comprising a P329G mutation that specifically binds to B-cell maturation antigen (BCMA) and immune effector cells (e.g., T cells, NK cells) engineered to express a molecular switch-regulated chimeric antigen receptor, and a therapeutic method using the combination, and to the use of the combination for treating diseases associated with BCMA expression, such as cancers that express or overexpress BCMA. Background Art

[0003] B cell maturation antigen (BCMA, also known as CD269, TNFRSF17) is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA is a type III transmembrane protein with a cysteine-rich domain (CRD) characteristic of TNFR family members in its extracellular domain (ECD), which forms a ligand-binding motif. BCMA ligands include B cell-activating factor (BAFF) and B cell proliferation-inducing ligand (APRIL). APRIL binds to BCMA with higher affinity, promoting tumor cell proliferation.

[0004] BCMA is primarily expressed on the surface of mature B cells, or plasma cells, and is not expressed in normal hematopoietic stem cells or non-hematopoietic tissues. BCMA signaling is essential for the survival of long-lasting bone marrow plasma cells but is not required for overall B cell homeostasis. Surface BCMA can be cleaved and shed by γ-secretase, resulting in soluble BCMA (sBCMA), which may reduce surface BCMA signaling by blocking BAFF / APRIL ligand binding. BCMA has been found to be overexpressed in multiple myeloma (MM) cells in preclinical models and human tumors. It upregulates both canonical and non-canonical NF-κB signaling, promoting MM cell growth, survival, and adhesion, inducing osteoclast activation, angiogenesis, metastasis, and immunosuppression. BCMA expression has become an important biomarker for the diagnosis of MM. Furthermore, elevated sBCMA levels in the serum of MM patients are positively correlated with the number of MM cells in the bone marrow, and changes in sBCMA concentration are closely associated with MM prognosis and treatment response.

[0005] Multiple myeloma (MM) is the second most common hematologic malignancy, occurring frequently in the elderly. It is characterized by the uncontrolled, progressive proliferation of plasma cell clones, which produce dysfunctional monoclonal immunoglobulins (Ig) or protein fragments (M proteins). The disease can reduce a patient's resistance to infection and cause severe skeletal deformities (accompanied by bone pain, pathological fractures, and hypercalcemia), anemia, renal failure, neurological complications, and hyperviscosity syndrome. Disease progression ultimately leads to death.

[0006] Multiple myeloma has a high incidence and mortality rate. The American Cancer Society's annual report, "Cancer Statistics 2018," published in CA: A Cancer Journal for Clinicians, estimates that in 2018, there were 1,735,350 new cancer cases in the United States (856,370 in men and 878,980 in women), and 609,640 cancer deaths (323,630 in men and 286,010 in women). Of these, 30,770 new cases of myeloma and 12,770 deaths were attributed to myeloma, accounting for 18% of all hematologic malignancies and 2% of all deaths from malignant tumors. According to the World Health Organization's cancer survey, in 2018, there were over 20,000 new cases of multiple myeloma and approximately 15,000 deaths in my country, making multiple myeloma the third most common hematologic malignancy in both incidence and mortality. The study of the International Myeloma Working Group (IMWG) showed that the 5-year overall survival rates of patients with International Staging System (R-ISS) stage I, II, and III were 82%, 62%, and 40%, respectively, and the 5-year progression-free survival rates were 55%, 36%, and 24%, respectively. The treatment options for multiple myeloma depend on age, physical status, comorbidities, disease aggressiveness, and related prognostic factors. With the development of new immunomodulators such as thalidomide and lenalidomide and the first-generation proteasome inhibitor (PI) Velcade, the treatment options for multiple myeloma have increased significantly. Since the introduction of bortezomib, the treatment of multiple myeloma has undergone dramatic changes in the past 10 years. Several randomized controlled clinical studies have shown that new drug treatments for multiple myeloma have significantly increased the remission rate and improved progression-free survival (PFS) and overall survival (OS). Overall, new treatments for multiple myeloma have significantly improved patient outcomes. However, due to residual myeloma stem cells, changes in the cellular microenvironment, activation of anti-apoptotic pathways, expression of drug-resistant genes, or clonal evolution, the vast majority of patients will eventually face disease relapse or progression. The low remission rate and short median survival of recurrent / refractory multiple myeloma (RRMM) seriously endanger the health of patients.

[0007] Abecma is the first CAR-T cell therapy targeting BCMA. It recognizes and binds to the BCMA protein on multiple myeloma cancer cells, causing the death of cancer cells expressing the BCMA protein. That is, it directly targets the surface antigen BCMA protein of tumor cells through the chimeric antigen receptor (CAR) on the CAR-T cell, thereby achieving the purpose of identifying and killing tumor cells. The shortcoming of this traditional chimeric antigen receptor T cell is that there is a lack of control over the activity of CAR-T cells after they are infused back into the body. After activation in vivo, these CAR-T cells will continue to recognize and kill cells expressing their target antigens. In some cases (such as when the tumor burden of the tumor patient is large), a large number of rapidly activated CAR-T cells will release massive inflammatory cytokines, causing patients to develop cytokine release syndrome (CRS), neurotoxicity (NT) and other serious side effects. A meta-study of 84 clinical trials containing 2,592 patients showed that the incidence of CRS and NT above grade 3 after receiving traditional CAR-T cell therapy was 29% and 28%, respectively. Although a large number of clinical trials have found that most patients who experience toxic reactions can recover quickly after receiving corresponding treatment and do not significantly affect the anti-tumor efficacy, the treatment of toxic and side effects takes up a lot of clinical resources and increases the physical, mental and economic burden on patients.

[0008] Since the antigens targeted by most CAR-T cells (e.g., Abecma) are tumor-associated antigens (TAAs) rather than tumor-specific antigens (TSAs), these TAAs, in addition to being expressed on tumor cells, are often also expressed at low levels in many normal tissues, especially important tissues and organs. CAR-T cells' recognition and killing of these normal tissues results in "on-target / off-tumor" toxicity, which the body may be able to tolerate in the short term, but if it cannot recover or alleviate in the long term, it may lead to serious side effects. For example, CAR-T cells targeting CD19 are used clinically to treat CD19-positive blood tumors. In addition to clearing tumor cells, CD19 CAR-T cells also kill normal B cells. Although the continued presence of CAR-T cells in the body is closely related to the patient's long-term recurrence-free survival, it also leads to long-term B cell dysplasia and humoral immunity deficiency, making it easy to cause infection. Clinical trials have shown that within 30 days of receiving CD19 CAR-T cell therapy, 27-36% of lymphoma patients develop bacterial infections, 9.2-28% develop viral infections one month later, and B cell recovery takes a median of 6.7 months. 31-64% of patients require immunoglobulin replacement therapy. Furthermore, sustained activation of CAR-T cells in the body can easily lead to functional exhaustion, impairing their anti-tumor effects and reducing their survival in the body, thereby diminishing long-term therapeutic efficacy.

[0009] To reduce the on-target / off-tumor toxicity of CAR-T cells, the following strategies are commonly used in existing technologies. One strategy is to design the antigen-binding domain contained in the CAR to target a target antigen that is highly expressed on the tumor surface but not expressed or expressed at low levels on normal tissues. Another strategy is to strictly control the dose of administered T cells, because excessive CAR-T cells will increase exponentially after being stimulated by antigens, making it more likely to cause on-target / off-tumor effects. Another strategy is to introduce an inducible suicide gene, such as the inducible Caspase-9 (iCasp9) suicide gene, when constructing CAR. When patients are observed to develop on-target / off-tumor toxicity, AP1903 (a dimerization chemical inducer that can activate iCasp9) is administered to induce apoptosis of CAR-T cells and reduce toxicity (Zhang Huihui et al., Preclinical study of suicide genes as a "safety switch" to control CAR-T cell toxicity, Chinese Journal of Oncology Biotherapy, 2021, 28(3): 225-231). There are also reports of using the herpes simplex virus thymidine kinase (HSV-TK) gene as a suicide gene to induce apoptosis of CAR-T cells by administering ganciclovir. In addition, there are also reports of using electroporation transfection methods to make T cells transiently express CAR, which exerts a therapeutic effect through transient killing function (Kenderian SS et al., CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia [J] Leukemia. 2015; 29(8): 1637–1647). However, the above-mentioned regulatory methods are all performed after toxicity occurs, and the toxicity alleviation effect depends on the effect and efficiency of drug clearance of CAR-T cells. Moreover, CAR-T cells cannot be restored after clearance, which affects the long-term anti-tumor efficacy.

[0010] However, these methods make it difficult to determine the correct time point for CAR-T cell clearance. In principle, there are two key time points where CAR-T cell activity needs to be adjusted or even terminated: (1) after the infusion of CAR-T cells, serious side effects occur; (2) after the CAR-T cells eliminate all tumor cells and then continue to attack important healthy tissues. Because CAR-T cells are "living" drugs, it is difficult to predict how they will react in the body, making it difficult to determine the correct time point for clearance. Therefore, if CAR-T cells can be equipped with a switch with two modes, "on and off", the "switch" can be turned on when needed to release the anti-tumor activity of CAR-T cells; after the CAR-T cells complete their task or when serious side effects occur, the "switch" can be turned off, thereby controlling and regulating the activity of CAR-T cells, which will greatly improve the safety and flexibility of CAR-T cell use.

[0011] Various "switch" strategies have been developed to control CAR-T cell activity, among which "modular" universal CAR-T cells hold significant clinical promise. Unlike traditional CAR-T cells, mod-uCAR-T cells do not directly target tumor cell antigens. Instead, they utilize an intermediate bridging molecule (adaptor) to "match" the CAR-T cells with tumor cells, thereby initiating the CAR-T cell anti-tumor response. Once the adapter is cleared from the body, the CAR-T cells become inactivated, effectively preventing off-target effects. Another benefit of this adapter-switch strategy is that by administering different, or even dual-targeting, adapter molecules simultaneously or sequentially, CAR-T cells can target different tumor cell antigens simultaneously or sequentially, potentially overcoming issues such as tumor recurrence and drug resistance caused by tumor heterogeneity. In this scenario, only the adapter molecule, not the CAR molecule, needs to be changed, making this "conditionally activated" CAR-T cell approach highly versatile.

[0012] There is a need in the art for a therapeutic approach that can conditionally activate CAR-T cells while applying them and controlling their toxicity, particularly a therapeutic approach with a specific dosage and / or dosing interval.

[0013] SUMMARY OF THE INVENTION

[0014] Conventional CAR-T cells targeting BCMA still face toxicity and relapse issues in the treatment of multiple myeloma (MM). A meta-study showed that the incidence of CRS and NT after conventional BCMA-targeted CAR-T cell therapy was 74% (95% CI, 56–91%) and 34% (95% CI, 24–43%), respectively, with grade 3 or higher events occurring in 25% (95% CI, 7–43%) and 12% (95% CI, 4–20%), respectively. Furthermore, the loss of plasma cells impairs humoral immunity in treated patients, increasing the incidence of infections. Among 128 patients with relapsed or refractory multiple myeloma (RRMM) treated with ide-cel, 69% experienced infections, with 22% experiencing grade 3 or higher infections. Many patients required anti-infective therapy, increased white blood cell growth factor (WGF) supplementation, and immunoglobulin replacement therapy. Similarly, among 97 patients with RRMM treated with cilta-cel, 56% and 20% experienced infections and grade 3 or higher infections, respectively. These clinical results suggest the need to develop a regulatable BCMA-targeted CAR-T cell therapy.

[0015] Based on the P329G mod-uCAR-T cell technology, the inventors have designed and constructed P329G CAR-T cells that target BCMA by binding to the Fc domain of an antibody specifically binding to BCMA containing the P329G mutation. Their specific and controllable anti-tumor effects have been validated in vitro and in vivo. Unlike traditional BCMA-targeted CAR-T cells that directly recognize and kill MM cells, the drug combination of the present invention comprises two components: the BCMA-specific P329G antibody and the P329G CAR-T cells. After the BCMA-specific P329G antibody recognizes BCMA-expressing tumor cells, the P329G antibody acts as an adaptor molecule to bridge the P329G CAR-T cells to the tumor cells. The P329G CAR-T cells are then redirected to the tumor cells by recognizing the Fc domain of the P329G antibody, resulting in target-specific tumor recognition and killing (see Figure 1B). In the therapeutic method using the drug combination of the present invention, the P329G antibody acts as a bridge connecting P329G CAR-T cells and tumor cells, playing the role of a "molecular switch" and regulating the activity of P329G CAR-T cells.

[0016] The CAR-T cell products developed with this technology have the following significant features: 1. By adjusting the frequency, dosage, route, and function of antibody administration, they effectively avoid the acute and chronic toxic side effects of traditional CAR-T cell therapy, promote the sustained proliferation and survival of CAR-T cells in vivo, and achieve a lasting anti-tumor effect. 2. By combining and sequentially administering antibodies, they effectively overcome clinical pain points such as primary tumor resistance and post-treatment recurrence without changing the CAR-T cells. 3. By combining antibodies targeting different types of tumor antigens, they achieve the goal of treating different tumors without changing the CAR-T cells. Given the mature and low-cost market for antibody drugs, this therapy will help reduce treatment costs and increase the accessibility of CAR-T cell therapy.

[0017] Therefore, in a first aspect, the present invention provides P329G mutant antibodies that can specifically bind to BCMA molecules as a "molecular switch" for immune effector cells (e.g., T cells, NK cells) expressing CAR polypeptides, including but not limited to ADI-38497 PG Ab (also referred to herein as "ADI-38497 PG antibody", "38497 PG Ab", "ADI-38497 PG IgG", "38497 PG IgG", "PG 38497 antibody").

[0018] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain variable region and a light chain variable region, wherein:

[0019] The heavy chain variable region comprises a CDR H1 as set forth in the amino acid sequence SSSYYWT (SEQ ID NO: 25) according to Kabat numbering, or a variant of the CDR H1 with no more than two amino acid changes or no more than one amino acid change; a CDR H2 as set forth in the amino acid sequence SISIAGSTYYNPSLKS (SEQ ID NO: 26), or a variant of the CDR H2 with no more than two amino acid changes or no more than one amino acid change; and a CDR H3 as set forth in the amino acid sequence DRGDQILDV (SEQ ID NO: 27), or a variant of the CDR H3 with no more than two amino acid changes or no more than one amino acid change; the light chain variable region comprises a CDR L1 as set forth in the amino acid sequence RASQSISRYLN (SEQ ID NO: 28), or a variant of the CDR L1 with no more than two amino acid changes or no more than one amino acid change; a CDR L2 as set forth in the amino acid sequence AASSLQS (SEQ ID NO: 29), or a variant of the CDR L2 with no more than 2 amino acid changes or no more than 1 amino acid change; and CDR L3 shown in the amino acid sequence QQKYFDIT (SEQ ID NO: 30), or a variant of said CDR L3 with no more than 2 amino acid changes or no more than 1 amino acid change; wherein the amino acid change is an addition, deletion or substitution of an amino acid.

[0020] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR H1 set forth in the amino acid sequence SSSYYWT (SEQ ID NO:25) according to Kabat numbering; a CDR H2 set forth in the amino acid sequence SISIAGSTYYNPSLKS (SEQ ID NO:26); and a CDR H3 set forth in the amino acid sequence DRGDQILDV (SEQ ID NO:27); and the light chain variable region comprises a CDR L1 set forth in the amino acid sequence RASQSISRYLN (SEQ ID NO:28) according to Kabat numbering; a CDR L2 set forth in the amino acid sequence AASSLQS (SEQ ID NO:29); and a CDR L3 set forth in the amino acid sequence QQKYFDIT (SEQ ID NO:30).

[0021] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain variable region, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 2, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.

[0022] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a light chain variable region, wherein the light chain variable region comprises the sequence of SEQ ID NO: 3, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.

[0023] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 2, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto; and the light chain variable region comprises the sequence of SEQ ID NO: 3, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.

[0024] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 2, and the light chain variable region comprises the sequence of SEQ ID NO: 3.

[0025] In some embodiments, the antibody of the present invention that specifically binds to a BCMA molecule is an IgG1, IgG2, IgG3, or IgG4 antibody; preferably, it is an IgG1 or IgG4 antibody; more preferably, it is an IgG1 antibody.

[0026] In some embodiments, the antigen-binding fragment of an antibody of the present invention that specifically binds to a BCMA molecule is Fab, Fab', F(ab')2, Fv, single-chain Fv, single-chain Fab, or diabody.

[0027] For the antibody or antigen-binding fragment that specifically binds to a BCMA molecule, an antibody having a mutant Fc domain is obtained by mutating the amino acid at position P329 according to EU numbering to glycine (G), wherein Fcγ receptor binding of the mutant Fc domain is reduced compared to Fcγ receptor binding of the unmutated parent antibody Fc domain.

[0028] In some embodiments, the mutant Fc domain is a mutant Fc domain of an IgG1, IgG2, IgG3 or IgG4 antibody, preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 or IgG4 antibody; more preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 antibody;

[0029] In some embodiments, the antibody or antigen-binding fragment that specifically binds to a BCMA molecule comprises a heavy chain constant region sequence set forth in SEQ ID NO:5, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, and wherein the amino acid at position P329 according to EU numbering is mutated to a G.

[0030] In some embodiments, the antibody or antigen-binding fragment that specifically binds to a BCMA molecule comprises a light chain constant region sequence set forth in SEQ ID NO:6, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.

[0031] In some embodiments, the antibody or antigen-binding fragment that specifically binds to a BCMA molecule comprises a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region comprises the amino acid sequence of SEQ ID NO:5, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto and wherein the amino acid at position P329 according to EU numbering is mutated to a G; and the light chain constant region comprises the amino acid sequence of SEQ ID NO:6, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.

[0032] In one embodiment, the antibody or antigen-binding fragment that specifically binds to a BCMA molecule comprises the heavy chain constant region sequence set forth in SEQ ID NO:5 and the light chain constant region sequence set forth in SEQ ID NO:6.

[0033] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds a BCMA molecule, comprising a heavy chain, wherein the heavy chain comprises the sequence of SEQ ID NO: 34, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto and wherein the amino acid at position P329 according to EU numbering is mutated to a G.

[0034] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a light chain, wherein the light chain comprises the sequence of SEQ ID NO: 35, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.

[0035] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO: 34, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto and wherein the amino acid at position P329 according to EU numbering is mutated to a G; and the light chain comprises the sequence of SEQ ID NO: 35, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto.

[0036] In some embodiments, the present invention provides an antibody or antigen-binding fragment that specifically binds to a BCMA molecule, comprising a heavy chain and a light chain, wherein the heavy chain comprises the sequence of SEQ ID NO: 34, and the light chain comprises the sequence of SEQ ID NO: 35.

[0037] In a second aspect, the present invention provides a nucleic acid encoding the antibody of the first aspect of the invention, a vector comprising the nucleic acid encoding the antibody, a cell comprising the nucleic acid molecule or vector, and a method for producing the antibody, the method comprising culturing a host cell into which an expression vector encoding the nucleic acid encoding the antibody or antigen-binding fragment that specifically binds to a BCMA molecule of the first aspect of the invention has been introduced under conditions suitable for expressing the nucleic acid encoding the antibody or antigen-binding fragment that specifically binds to a BCMA molecule of the first aspect of the invention, isolating the antibody or antigen-binding fragment that specifically binds to a BCMA molecule, and optionally, the method further comprises recovering the antibody or antigen-binding fragment that specifically binds to a BCMA molecule from the host cell. Preferably, the host cell is prokaryotic or eukaryotic, more preferably selected from Escherichia coli cells, yeast cells, mammalian cells, or other cells suitable for producing antibodies or antigen-binding fragments thereof, and most preferably, the host cell is a HEK293 cell or a CHO cell.

[0038] In a third aspect, the present invention provides a pharmaceutical combination comprising

[0039] (i) a first component selected from immune effector cells (e.g., T cells, NK cells) expressing a molecular switch-regulated CAR polypeptide, a nucleic acid molecule encoding the CAR polypeptide, a vector comprising the nucleic acid molecule, and any combination thereof; and

[0040] (ii) a second component, which is an antibody or antigen-binding fragment comprising a P329G mutation that specifically binds to a BCMA molecule (also referred to as a P329G mutant antibody), for example, the P329G mutant antibody of the first aspect of the invention, and

[0041] optionally pharmaceutically acceptable excipients;

[0042] Wherein, the molecular switch regulatory CAR polypeptide comprises

[0043] (1) A humanized anti-P329G mutant scFv sequence, wherein the scFv sequence comprises the following sequence that is capable of specifically binding to the Fc domain of an antibody comprising the P329G mutation but is unable to specifically bind to the Fc domain of an unmutated parent antibody:

[0044] (i) a heavy chain variable region comprising a

[0045] (a) a heavy chain complementarity determining region CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 19), or a variant of said CDR H1 having no more than two amino acid changes or no more than one amino acid change;

[0046] (b) CDR H2 shown in the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 20), or a variant of said CDR H2 with no more than 2 amino acid changes or no more than 1 amino acid change; and

[0047] (c) CDR H3 represented by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 21), or a variant of said CDR H3 having no more than two amino acid changes or no more than one amino acid change; and

[0048] (ii) a light chain variable region comprising a

[0049] (d) a light chain complementarity determining region (CDR L) 1 represented by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 22), or a variant of said CDR L1 having no more than two amino acid changes or no more than one amino acid change;

[0050] (e) CDR L2 shown in the amino acid sequence GTNCRAP (SEQ ID NO: 23), or a variant of said CDR L2 with no more than 2 amino acid changes or no more than 1 amino acid change; and

[0051] (f) CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 24), or a variant of said CDR L3 having no more than two amino acid changes or no more than one amino acid change;

[0052] wherein the amino acid change is an addition, deletion or substitution of an amino acid;

[0053] (2) a hinge region / spacer region selected from

[0054] (i)(G4S) n 、(SG4) n or G4 (SG4) n A peptide linker, wherein "n" is an integer from 1 to 10, such as an integer from 1 to 4; for example, the sequence shown in SEQ ID NO: 14;

[0055] (ii) a CD8α hinge region or a variant thereof having 1-5 amino acid modifications, for example, the sequence shown in SEQ ID NO: 18 or a variant thereof having 1-2 amino acid modifications;

[0056] (3) a transmembrane region (TM), which is selected from the CD8 transmembrane domain or a variant thereof having 1-5 amino acid modifications, for example, the sequence shown in SEQ ID NO: 15 or a variant thereof having 1-2 amino acid modifications;

[0057] (4) a costimulatory signaling domain (CSD) selected from the 4-1BB costimulatory domain or a variant thereof having 1-5 amino acid modifications, for example, the sequence shown in SEQ ID NO: 16 or a variant thereof having 1-2 amino acid modifications;

[0058] (5) a stimulatory signaling domain (SSD), which is a CD3ζ signaling domain or a variant thereof having 1-10 amino acid modifications, for example, the sequence shown in SEQ ID NO: 17 or a variant thereof having 1-10 or 1-5 amino acid modifications;

[0059] The amino acid modification is the addition, deletion or substitution of an amino acid.

[0060] In some embodiments, the molecular switch-regulated CAR polypeptide in the pharmaceutical combination of the present invention comprises

[0061] (1) A humanized anti-P329G mutant scFv sequence, wherein the scFv sequence comprises the following sequence that is capable of specifically binding to the Fc domain of an antibody comprising the P329G mutation but is unable to specifically bind to the Fc domain of an unmutated parent antibody:

[0062] (i) a heavy chain variable region comprising a

[0063] (a) CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 19);

[0064] (b) CDR H2 represented by the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 20); and

[0065] (c) CDR H3 represented by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 21); and

[0066] (ii) a light chain variable region comprising a

[0067] (d) CDR L1 represented by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 22);

[0068] (e) CDR L2 represented by the amino acid sequence GTNCRAP (SEQ ID NO: 23); and

[0069] (f) CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 24);

[0070] For example, (i) a heavy chain variable region comprising the sequence of SEQ ID NO: 12, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and

[0071] (ii) a light chain variable region comprising the sequence of SEQ ID NO: 13, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto;

[0072] For example, (i) a heavy chain variable region comprising the sequence of SEQ ID NO: 12, and (ii) a light chain variable region comprising the sequence of SEQ ID NO: 13;

[0073] (2) a hinge region / spacer region selected from

[0074] (i)(G4S) n 、(SG4) n or G4 (SG4) n A peptide linker, wherein "n" is an integer from 1 to 4, such as the sequence shown in SEQ ID NO: 14;

[0075] (ii) the CD8α hinge region sequence shown in SEQ ID NO: 18 or a variant thereof having one amino acid modification;

[0076] (3) a transmembrane region (TM) selected from the CD8 transmembrane domain shown in SEQ ID NO: 15 or a variant thereof having one amino acid modification;

[0077] (4) a costimulatory signaling domain (CSD) selected from the 4-1BB costimulatory domain shown in SEQ ID NO: 16 or a variant thereof having one amino acid modification;

[0078] (5) a stimulatory signaling domain (SSD) selected from the CD3ζ signaling domain shown in SEQ ID NO: 17 or a variant thereof having one amino acid modification;

[0079] The amino acid modification is the addition, deletion or substitution of an amino acid.

[0080] In some embodiments, the molecular switch-regulated CAR polypeptide in the pharmaceutical combination of the present invention further comprises a signal peptide sequence at the N-terminus, for example, the signal peptide sequence shown in SEQ ID NO: 11.

[0081] In some embodiments, the molecular switch-regulated CAR polypeptide described in the pharmaceutical combination of the present invention has the amino acid sequence shown in SEQ ID NO: 1, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.

[0082] In a fourth aspect, the present invention provides a nucleic acid encoding the molecular switch-regulated CAR polypeptide described in the drug combination of the present invention, a vector comprising a nucleic acid encoding the CAR polypeptide, and a cell comprising the CAR nucleic acid molecule or vector, or a cell expressing the CAR polypeptide, preferably, the cell is an autologous T cell or an allogeneic T cell.

[0083] In some embodiments, the nucleic acid molecule encoding the molecular switch-regulated CAR polypeptide described in the drug combination of the present invention is a nucleic acid molecule encoding the amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.

[0084] In some embodiments, the vector comprising the nucleic acid molecule encoding the molecular switch-regulated CAR polypeptide described in the pharmaceutical combination of the present invention is selected from a DNA vector, an RNA vector, a plasmid, a lentiviral vector, an adenoviral vector or a retroviral vector.

[0085] In some embodiments, the immune effector cells in the drug combination of the present invention are autologous T cells, NK cells or allogeneic T cells, T cells and NK cells expressing the molecular switch-regulated CAR polypeptide of the present invention. For example, the immune effector cells are T cells and NK cells prepared from human peripheral blood mononuclear cells (PBMC) and expressing the molecular switch-regulated CAR polypeptide of the present invention.

[0086] In some embodiments, the present invention utilizes primary P329G CAR-T cells prepared from human PBMCs derived from multiple different donors and a humanized anti-BCMA antibody with the P329G mutation to evaluate the effector function of P329G CAR-T cells against BCMA-expressing tumor cells through the antibody in an in vitro co-culture system. Thus, the anti-BCMA antibody with the P329G mutation can act as a "molecular switch" to regulate the recognition and killing activity of P329G CAR-T cells against BCMA-positive tumor cells. This in vitro effector function is comparable to that of traditional CAR-T cells that directly target BCMA-positive tumor cells, but the activity of traditional CAR-T cells is not dependent on the P329G mutation antibody.

[0087] In some embodiments, the present invention verifies the anti-tumor effect of P329G CAR-T cells combined with P329G mutant antibodies in immunodeficient mice inoculated with tumors derived from BCMA-positive human tumor cell lines, and studies the dosage and interval of antibody administration.

[0088] In vitro and in vivo experiments demonstrated that only in the presence of the P329G antibody could P329G CAR-T cells activate their effector function, recognizing and killing BCMA-positive tumor cells. Adjusting the P329G antibody dosage and dosing interval could modulate the extent of P329G CAR-T cell proliferation in vivo and the intensity of its anti-tumor activity. Given that BCMA transmits tumor-promoting signals after binding to its ligand, the P329G antibody can exert its anti-tumor effects by blocking these signals. Therefore, the BCMA-specific P329G antibody and P329G CAR-T cells can produce a synergistic anti-tumor effect.

[0089] In some embodiments, for the pharmaceutical combination of the present invention, (i) immune effector cells expressing the CAR polypeptide of the present invention are cultured at a rate of approximately 0.5×10 6 cells / kg body weight - approximately 5×10 6 cells / kg body weight, for example, approximately 0.75×10 6 cells / kg body weight, 1×10 6cells / kg body weight, 1.5×10 6 cells / kg body weight, 2×10 6 cells / kg body weight, 2.5×10 6 cells / kg body weight, 3×10 6 cells / kg body weight, 3.5×10 6 cells / kg body weight, 4×10 6 cells / kg body weight, 4.5×10 6 cells / kg body weight, 5×10 6 cells / kg body weight in a single or multiple intravenous administration to the subject; and

[0090] (ii) The P329G mutant antibody described in the pharmaceutical combination of the present invention is administered to the subject in the form of a dosage unit of about 0.1-3 mg / kg, preferably about 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, preferably parenterally, more preferably intravenously.

[0091] In some embodiments, (i) and (ii) in the pharmaceutical combination of the present invention are administered separately, simultaneously or sequentially, for example, (ii) is administered on the first day, (i) is administered intravenously on the same day or the next day, and then (ii) is administered multiple times at a certain frequency.

[0092] In some preferred embodiments, (i) and (ii) in the pharmaceutical combination of the present invention are administered according to the following regimen:

[0093] On the first day, (ii) and (i) are sequentially administered with an interval of about 1-5 hours (e.g., an interval of about 1, 2, 3, 4, or 5 hours). Preferably, (ii) is administered on the first day, and (i) is administered with an interval of about 1-5 hours (e.g., an interval of about 1, 2, 3, 4, or 5 hours); or (ii) is administered on the first day and (i) is administered on the second day, with an interval of about 24 hours.

[0094] Taking the first day as the starting day, administer (ii) every 1 week (QW), 2 weeks (Q2W) or every 3 weeks (Q3W) in the first cycle; and optionally

[0095] The second to nth cycles: (ii) is administered every three weeks (Q3W) in each cycle.

[0096] In some embodiments, each dosing cycle is 21 days or 28 days.

[0097] In some embodiments, the drug is administered for at least 2-3 cycles. In some embodiments, the drug is administered for at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 cycles or more.

[0098] In a fourth aspect, the present invention provides a drug combination of the present invention or use thereof, for treating a BCMA-related disease in a subject, comprising administering to the subject a therapeutically effective amount of the drug combination defined in the aforementioned third aspect, wherein the BCMA-related disease is, for example, a cancer that expresses or overexpresses BCMA, the cancer is, for example, multiple myeloma, such as refractory multiple myeloma or relapsed multiple myeloma, for example, the multiple myeloma is relapsed / refractory multiple myeloma (RRMM).

[0099] In a fifth aspect, the present invention provides use of the drug combination of the present invention in the preparation of a medicament for treating a BCMA-related disease, such as a cancer that expresses or overexpresses BCMA, such as multiple myeloma, such as refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma (RRMM).

[0100] In a sixth aspect, the present invention provides a method for treating a disease associated with BCMA, the method comprising administering to a subject a therapeutically effective amount of a drug combination of the present invention, wherein the disease is, for example, a cancer that expresses or overexpresses BCMA, such as multiple myeloma, for example, refractory multiple myeloma or relapsed multiple myeloma, for example, the multiple myeloma is relapsed / refractory multiple myeloma (RRMM).

[0101] In a seventh aspect, the present invention provides a kit of parts comprising the pharmaceutical combination as defined in the third aspect above, preferably the kit is in the form of pharmaceutical dosage units.

[0102] Thus, the present invention first obtains a high-affinity BCMA-specific P329G antibody through in vitro binding ability, affinity and Fc effector function tests. The antibody can simultaneously bind to the BCMA antigen and the P329G CAR molecule to exert a bridging effect. Secondly, in the third aspect, the present invention uses the constructed P329G CAR structural molecule and combines the P329G CAR-T cells prepared by the CAR molecule with the BCMA-specific P329G antibody, and then co-cultures them with BCMA-positive MM cells in vitro to construct an in vitro co-culture system. In this system, the effect of the P329G antibody as a "molecular switch" to regulate the activity of the P329G CAR-T cells was verified, that is, only in the presence of the P329G mutant antibody can the P329G CAR-T cells be activated, proliferate, secrete effector cytokines and produce a killing effect, and these effects are P329G antibody dose-dependent. As the antibody dose increases, the recognition and killing effects of the P329G CAR-T cells are enhanced. However, WT antibodies without the P329G mutation cannot stimulate the effector function of P329G CAR-T cells.

[0103] In addition, in vitro experiments of the present invention showed that soluble BCMA antigen did not affect the activity of P329G CAR-T cells when used in combination with the BCMA-specific P329G antibody, while soluble BCMA antigen had a significant inhibitory effect on traditional CAR-T cells. In subcutaneous and systemic tumor-bearing immunodeficient mouse models with high and low BCMA expression, the P329G CAR-T cells of the present invention combined with the P329G antibody produced a good anti-tumor effect that was at least equivalent to that of traditional CAR-T cells. However, the degree of in vivo expansion of P329G CAR-T cells was significantly lower than that of traditional CAR-T cells, suggesting that while producing comparable anti-tumor effects, P329G CAR-T cells may induce lower acute toxic side effects such as CRS and NT. Furthermore, by adjusting the dosage and interval of P329G antibody administration, the degree of in vivo expansion of P329G CAR-T cells and the intensity of the anti-tumor effect can be adjusted. After tumor clearance, stopping the administration of P329G antibody can still maintain a sustained anti-tumor effect. This lays the foundation for "turning off" the activity of P329G CAR-T cells in clinical applications, maintaining a sustained anti-tumor effect while restoring normal plasma cell numbers and humoral immunity to reduce long-term toxic side effects such as infection.

[0104] The toxicology experiments of the present invention also showed that the combination of P329G CAR-T cells and P329G antibodies did not produce obvious toxicity, thus laying the foundation for clinical transformation.

[0105] In some embodiments, after administration of the therapy of the present invention, the probability of the subject developing CRS or ICANS is low, such as less than 50%, such as lower than that of existing BCMA-CAR-T products.

[0106] In some embodiments, the therapies of the present invention have a good safety and / or tolerability profile.

[0107] In some embodiments, the second component (e.g., an anti-BCMA antibody) is capable of modulating the activity of the first component, particularly the cellular activity of CAR-T cells.

[0108] In some embodiments, the therapy of the present invention can partially relieve the disease in the subject. Clinical studies have shown that a total of 11 patients were enrolled, of whom 5 patients achieved PR or above.

[0109] In some specific embodiments, the drug combination or therapy of the present invention achieves a relatively good effect in terms of safety. (1) CRS: As of the data cutoff date, in the two studies, 5 of the 11 subjects developed CRS of varying degrees, with a CRS incidence rate of 45.5%, which is lower than that of existing BCMA-CART products. Under the current circumstances, the CRS that has occurred is relatively controllable. Most subjects have improved or been cured after treatment;

[0110] (2) ICANS: As of the data cutoff date, no neurological toxicity events were observed in the two studies.

[0111] BRIEF DESCRIPTION OF THE DRAWINGS

[0112] The preferred embodiments of the present invention described in detail below will be better understood when read in conjunction with the following drawings. For the purpose of illustrating the present invention, the drawings show presently preferred embodiments. However, it should be understood that the present invention is not limited to the precise arrangements and means of the embodiments shown in the drawings.

[0113] Figure 1A shows the CD3 expression of HuR968B and Blue21 CAR constructed in Example 1-1 after T cells were transduced. + cells, CD4 + 、CD8 + CAR expression in T cell subsets.

[0114] Figure 1B shows the mechanism of action of P329G CAR-T cells targeting BCMA-expressing target cells through P329G antibody-mediated targeting. The structures of 8 CAR constructs. In the figure, "SP" represents a signal peptide; "TMD" represents a transmembrane domain; "ICD" represents an intracellular domain; "CSD" represents a costimulatory domain; and "SSD" represents a stimulatory signaling domain. In the construct of the PG CAR in the figure, the extracellular domain comprises an antigen-binding portion that can specifically bind to a mutant Fc domain containing a P329G mutation, and the antigen-binding portion comprises a heavy chain variable region (VH) and a light chain variable region (VHL).

[0115] FIG2A shows a schematic diagram of a method for measuring antibody affinity using surface plasmon resonance (SPR).

[0116] Figure 2B shows representative affinity profiles of ADI-38497 PG antibody to recombinant human, cynomolgus monkey, mouse, rat, and rabbit BCMA proteins measured by SPR.

[0117] Figure 2C shows the binding ability of P329G BCMA antibody to CHO-GS cells stably expressing human, cynomolgus monkey, and mouse BCMA.

[0118] FIG2D shows the binding activity of the P329G BCMA antibody to BCMA-expressing positive multiple myeloma cell lines MM.1s, RPMI8226, U266, H929, L363, and AMO1.

[0119] FIG3A shows a schematic diagram of the detection of the affinity between the anti-P329G mutation specific single-chain antibody-rabbit Fc fusion protein and the ADI-38497 P329G mutation antibody using surface plasmon resonance (SPR).

[0120] Figure 3B shows representative affinity profiles of ADI-38497 PG antibody and wild-type antibody binding to anti-PG scFv fusion protein measured by SPR.

[0121] FIG3C shows a schematic diagram of a method for measuring antibody affinity using surface plasmon resonance (SPR).

[0122] Figure 3D shows representative affinity profiles of ADI-38497 PG antibody and wild-type antibody fusion protein with anti-PG scFv (in the middle, the extracellular domain of P329G CAR contains anti-PG scFv) measured by SPR.

[0123] Figure 3E shows the binding ability of ADI-38497 WT antibody and ADI-38497 PG antibody to P329G CAR-T cells.

[0124] Figure 4A shows the ability of ADI-38497 WT antibody and ADI-38497 PG antibody to mediate ADCC killing.

[0125] FIG4B shows the ability of ADI-38497 WT antibody and ADI-38497 PG antibody to mediate ADCP killing.

[0126] Figure 4C shows the ability of ADI-38497 PG antibody to mediate target cell lysis.

[0127] Figure 5A shows that ADI-38497 PG antibody containing P329G mutation specifically mediates CAR against H929 cells. + -T activation.

[0128] Figure 5B shows the activation effect of different BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, GSK PG IgG) on HuR968B CAR-T cells induced by L363 target cells.

[0129] Figure 5C shows the proliferation of HuR968B CAR-T cells after stimulation with coated ADI-38497WT antibody or ADI-38497 PG antibody.

[0130] Figure 5D shows the release of effector cytokines secreted by HuR968B CAR-T cells after co-culture with H929 cells and RPMI8226 cells and the addition of different concentrations of BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or GSK PG IgG as a positive control).

[0131] Figure 5E shows the release of effector cytokines secreted by HuR968B CAR-T cells after co-culture with different tumor cells and the addition of different concentrations of BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or GSK PG IgG).

[0132] Figure 5F shows the effect of different BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or GSK PG IgG) on HuR968B CAR-T cells against tumor cells with different BCMA expression levels (H929 ++ Cells, RPMI8226 +++ cells, AMO1 + cells and L363 + cell) killing effect.

[0133] Figure 5G shows that P329G BCMA antibody induces CAR-T to produce a killing effect on tumor cells.

[0134] Figure 6 shows the effects of different concentrations of free BCMA protein on the killing effect of HuR968B CAR-T and Blue21 CAR-T cells.

[0135] Figures 7A and 7B show the results of pharmacokinetic experiments of ADI-38497 PG antibody in mice.

[0136] Figure 8A shows the therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells that highly express BCMA. In the figure, "cCAR-T" represents conventional CAR-T, i.e., Blue21 CAR-T.

[0137] Figure 8B shows the changes in body weight of immunodeficient tumor-bearing mice treated with different doses of PG antibody combined with PG CAR-T cells after subcutaneous inoculation of human H929 tumor cells highly expressing BCMA.

[0138] Figure 8C shows the expansion of PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells that highly express BCMA and treated with different doses of PG antibodies combined with PG CAR-T cells.

[0139] Figure 9A shows the therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human L363 low-expressing BCMA tumor cells. In the figure, "cCAR-T" represents conventional CAR-T, i.e., Blue21 CAR-T.

[0140] Figure 9B shows the changes in body weight of immunodeficient tumor-bearing mice treated with different doses of PG antibody combined with PG CAR-T cells after subcutaneous inoculation of human L363 low-expressing BCMA tumor cells.

[0141] Figure 9C shows the expansion of PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human L363 low-expressing BCMA tumor cells and treated with different doses of PG antibodies combined with PG CAR-T cells.

[0142] FIG10A shows the therapeutic effect of PG antibody combined with different doses of PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells.

[0143] Figure 10B shows the expansion of PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells when PG antibodies were combined with different doses of PG CAR-T cells for treatment.

[0144] FIG11A shows the administration frequency of PG antibody in the experiment of Example 11-1.

[0145] FIG11B shows the therapeutic effect of different dosing frequencies of PG antibody in combination with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells.

[0146] Figure 11C shows the expansion of PG CAR-T cells in mice in the experiment of Example 11-1.

[0147] Figure 12A shows fluorescence images of the therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice inoculated with human H929-luc tumor cells via the tail vein.

[0148] Figure 12B shows the therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice inoculated with human H929-luc tumor cells via the tail vein.

[0149] Figure 12C shows the changes in body weight of immunodeficient tumor-bearing mice inoculated with human H929-luc tumor cells via the tail vein and treated with different doses of PG antibody combined with PG CAR-T cells.

[0150] FIG13A shows the therapeutic effect of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells.

[0151] Figure 13B shows the changes in body weight of immunodeficient tumor-bearing mice treated with PG antibody combined with PG CAR-T cells after subcutaneous inoculation of human H929 tumor cells.

[0152] Figures 13C and 13D show the hematological and blood biochemical test results of mice when PG antibody combined with PG CAR-T cells were treated in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells.

[0153] FIG14 shows a swimming chart showing the efficacy evaluation after administration of the C-BCMA-CAR-PG-01 regimen.

[0154] FIG15 shows a swimming chart showing the efficacy evaluation after administration of the C-BCMA-CAR-PG-02 regimen.

[0155] Figure 16 shows the CAR-T cell expansion diagram after administration of the C-BCMA-CAR-PG-01 regimen and the C-BCMA-CAR-PG-02 regimen.

[0156] Figure 17 shows the changes in antibody concentration after administration of the C-BCMA-CAR-PG-01 regimen and the C-BCMA-CAR-PG-02 regimen.

[0157] FIG18 shows a cell expansion diagram of a typical case 1 after administration of the C-BCMA-CAR-PG-02 regimen.

[0158] FIG19 shows a graph showing changes in cytokines in a typical case 1 after administration of the C-BCMA-CAR-PG-02 regimen.

[0159] FIG20 shows a cell expansion diagram of a typical case 2 after administration of the C-BCMA-CAR-PG-01 regimen.

[0160] FIG21 shows the cytokine changes of typical case 2 after administration of the C-BCMA-CAR-PG-01 regimen.

[0161] Detailed Description of the Invention

[0162] Unless otherwise limited, all technical and scientific terms used herein have the same meaning as those of ordinary skill in the art to which the present invention belongs. All publications, patent applications, patents and other references mentioned herein are incorporated by reference in their entirety. In addition, the materials, methods and examples described herein are merely illustrative and are not intended to be restrictive. Other features, objects and advantages of the present invention will become apparent from this specification and the accompanying drawings and from the appended claims.

[0163] I. Definition

[0164] To interpret this specification, the following definitions will apply, and wherever appropriate, terms used in the singular may also include the plural, and vice versa. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting.

[0165] The term "about" when used in conjunction with a numerical value is meant to encompass the numerical value within a range having a lower limit that is 5% less than the specified numerical value and an upper limit that is 5% greater than the specified numerical value.

[0166] As used herein, the term "and / or" means any one of the alternatives or two or more of the alternatives.

[0167] In this document, when the terms "comprising" or "including" are used, unless otherwise specified, it also covers the situation consisting of the recited elements, integers or steps. For example, when referring to an antibody variable region "comprising" a specific sequence, it is also intended to cover the antibody variable region consisting of the specific sequence.

[0168] The terms "BCMA" and "B cell maturation antigen" are used interchangeably and include variants, isoforms, species homologs, and analogs of human BCMA that share at least one epitope with BCMA (e.g., human BCMA). BCMA protein may also include fragments of BCMA, such as the extracellular domain and fragments of the extracellular domain, for example, fragments that retain the ability to bind to any of the antibodies of the present invention.

[0169] As used herein, the terms "BCMA antibody," "antibody against BCMA," "antibody that specifically binds to BCMA," "antibody that specifically targets BCMA," and "antibody that specifically recognizes BCMA" are used interchangeably and refer to an antibody that can specifically bind to B-cell maturation antigen (BCMA).

[0170] The term "antibody" is used in the broadest sense herein to refer to a protein comprising an antigen binding site, encompassing natural and artificial antibodies of various structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), single-chain antibodies, complete antibodies, and antibody fragments. Preferably, the antibody of the present invention is a single domain antibody or a heavy chain antibody.

[0171] "Antibody fragment" or "antigen-binding fragment" are used interchangeably herein to refer to a molecule other than an intact antibody that comprises a portion of an intact antibody and binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fab, Fab', F(ab')2, Fv, single-chain Fv, single-chain Fab, and diabody.

[0172] The term "scFv" refers to a fusion protein comprising at least one antibody fragment comprising a light chain variable region and at least one antibody fragment comprising a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region are optionally continuously connected by a flexible short polypeptide linker and can be expressed as a single chain polypeptide, and wherein the scFv retains the specificity of the intact antibody from which it is derived. Unless otherwise indicated, as used herein, scFv can have the VL variable region and the VH variable region in any order (e.g., relative to the N-terminus and C-terminus of the polypeptide), and the scFv can comprise VL-linker-VH or can comprise VH-linker-VL.

[0173] "Complementarity determining region" or "CDR region" or "CDR" or "hypervariable region" is a region in an antibody variable domain that is highly variable in sequence and forms structurally determined loops ("hypervariable loops") and / or contains antigen contact residues ("antigen contact points"). CDRs are primarily responsible for binding to antigenic epitopes. The CDRs of the heavy and light chains are typically referred to as CDR1, CDR2, and CDR3, and are numbered sequentially starting from the N-terminus. The CDRs located within the antibody heavy chain variable domain are referred to as CDR H1, CDR H2, and CDR H3, while the CDRs located within the antibody light chain variable domain are referred to as CDR L1, CDR L2, and CDR L3. In a given light chain variable region or heavy chain variable region amino acid sequence, the precise amino acid sequence boundaries of each CDR can be determined using any one or a combination of a number of well-known antibody CDR assignment systems, including, for example, Chothia based on the three-dimensional structure of antibodies and the topology of the CDR loops (Chothia et al., (1989) Nature 342:877-883, Al-Lazikani et al., "Standard conformations for the canonical structures of immunoglobulins", Journal of Molecular Biology, 273, 927-948 (1997)), Kabat based on antibody sequence variability (Kabat et al., Sequences of Proteins of Immunological Interest, 4th Edition, US Department of Health and Human Services, National Institutes of Health (1987)), AbM (University of Bath), Contact (University College London), International ImMunoGeneTics database (IMGT) (world wide web imgt.cines.fr / ), and the North CDR definition based on affinity propagation clustering using a large number of crystal structures.

[0174] Unless otherwise indicated, in the present invention, the term "CDR" or "CDR sequence" encompasses CDR sequences determined in any of the above-mentioned ways.

[0175] CDR can also be determined based on having the same Kabat numbering position as a reference CDR sequence (e.g., any of the CDRs exemplified herein). In the present invention, when referring to antibody variable regions and specific CDR sequences (including heavy chain variable region residues), it refers to the numbering position according to the Kabat numbering system.

[0176] Although CDR is different between antibodies, only a limited number of amino acid positions in CDR are directly involved in antigen binding. Using at least two of the Kabat, Chothia, AbM and Contact methods, the minimum overlapping region can be determined, thereby providing a "minimum binding unit" for antigen binding. The minimum binding unit can be a sub-portion of a CDR. As those skilled in the art will appreciate, the residues of the remainder of the CDR sequence can be determined by the structure and protein folding of the antibody. Therefore, the present invention also contemplates variants of any CDR provided herein. For example, in a variant of a CDR, the amino acid residues of the minimum binding unit can remain unchanged, while the remaining CDR residues defined according to Kabat or Chothia or AbM can be replaced by conservative amino acid residues.

[0177] The term "chimeric antibody" is an antibody molecule in which (a) the constant region or a portion thereof is changed, replaced or exchanged so that the antigen binding site is connected to a constant region of a different or altered class and / or species or a completely different molecule (e.g., enzyme, toxin, hormone, growth factor, drug) that confers new properties to the chimeric antibody; or (b) the variable region or a portion thereof is changed, replaced or exchanged with a variable region having a different or altered antigenic specificity. For example, a mouse antibody can be modified by replacing its constant region with a constant region from a human immunoglobulin. Due to the replacement with a human constant region, the chimeric antibody can retain its specificity in recognizing the antigen while having reduced antigenicity in humans as compared to the original mouse antibody.

[0178] "Humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs. In some embodiments, all or substantially all of the CDRs (e.g., CDRs) in the humanized antibody correspond to those of non-human antibodies, and all or substantially all of the FRs correspond to those of human antibodies. Humanized antibodies optionally can comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody (e.g., a non-human antibody) refers to a humanized antibody.

[0179] A "human antibody" refers to an antibody having an amino acid sequence that corresponds to the amino acid sequence of an antibody produced by a human or human cell, or derived from a non-human source, utilizing a human antibody library or other human antibody encoding sequences. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.

[0180] The term "Fc region" refers to the C-terminal region of an immunoglobulin heavy chain, including native sequence Fc regions and variant Fc regions. The human IgG heavy chain Fc region is generally defined as the segment from the amino acid residue at position Cys226 or Pro230 to the carboxyl terminus. The lysine residue at position 447 at the C-terminus of the Fc region (according to the EU numbering system) may be present or absent. Thus, a complete antibody composition may include antibody populations in which all K447 residues have been eliminated, antibody populations in which no K447 residue has been eliminated, or antibody populations that are a mixture of antibodies with and without K447 residues.

[0181] In certain embodiments, the Fc region of an immunoglobulin comprises two constant domains, namely, CH2 and CH3. In other embodiments, the Fc region of an immunoglobulin comprises three constant domains, namely, CH2, CH3, and CH4.

[0182] IgG binding to Fcγ receptors or C1q depends on residues located in the hinge region and the CH2 domain. Two regions of the CH2 domain are critical for FcγR and complement C1q binding and have unique sequences in IgG2 and IgG4. Substitution of residues 233-236 in human IgG1 and IgG2 and residues 327, 330, and 331 in human IgG4 has been shown to significantly reduce ADCC and CDC activity (Armour et al., Eur. J. Immunol. 29 (8), 1999, 2613-2624; Shields et al., J. Biol. Chem. 276 (9), 2001, 6591-6604).

[0183] "Functional Fc region" and "functional Fc region" and similar terms are used interchangeably to refer to an Fc region that possesses the effector function of a wild-type Fc region. In some embodiments, the Fc region comprises the amino acid sequence of SEQ ID NO:9, or an amino acid sequence that is at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to said amino acid sequence.

[0184] "Variant Fc region," "Fc mutant," "Fc region carrying a mutation," "mutant Fc region," "Fc region variant," "Fc variant," "variant Fc region," and "mutated Fc region" and similar terms are used interchangeably to refer to an Fc region that comprises at least one amino acid modification that is different from a native sequence Fc region / wild-type Fc region.

[0185] In some embodiments, the variant Fc region comprises an amino acid sequence that differs from the amino acid sequence of the native sequence Fc region by one or more amino acid substitutions, deletions or additions. In some embodiments, the variant Fc region has at least one amino acid substitution compared to the Fc region of wild-type IgG, and the at least one amino acid substitution is to replace the amino acid at position P329 according to EU numbering with glycine (G). In some embodiments, the Fc region comprises the amino acid sequence described in SEQ ID NO: 10, or an amino acid sequence having at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto and having a P329G mutation.

[0186] "Fc receptor" or "FcR" refers to a molecule that binds to the Fc region of an antibody. In some embodiments, the FcR is a native human FcR. In some embodiments, the FcR is a receptor that binds to IgG antibodies, namely, an FcγR, including three receptors: FcγRI (CD64), FcγRII (CD32), and FcγRIII (CD16), as well as allelic variants and alternatively spliced ​​forms of these receptors. FcγRII receptors include FcγRIIA and FcγRIIB, and FcγRIII receptors include FcγRIIIA and FcγRIIIB.

[0187] The term "effector function" refers to those biological activities attributable to the Fc region of an immunoglobulin that vary with the immunoglobulin isotype. Examples of immunoglobulin effector functions include: Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen uptake by antigen-presenting cells, C1q binding and complement-dependent cytotoxicity (CDC), downregulation of cell surface receptors (e.g., B cell receptor), and B cell activation.

[0188] The term "antibody-dependent cell-mediated cytotoxicity (ADCC)" is one of the main mechanisms by which certain cytotoxic effector cells (e.g., natural killer (NK) cells) mediate the killing of target cells and foreign host cells. In some embodiments, the chimeric antigen receptor of the present invention provides antibody-dependent cellular cytotoxicity of T lymphocytes and enhances the antibody-dependent cellular cytotoxicity of NK cells. The chimeric antigen receptor of the present invention binds to an antibody (or other anti-tumor molecule comprising an Fc portion) that binds to tumor cells, thereby inducing activation of T cells expressing the chimeric antigen receptor, continued proliferation, and exerting specific cytotoxicity against target cancer cells mediated by the antibody (or other anti-tumor molecule comprising an Fc portion).

[0189] The term "antibody-dependent cellular phagocytosis (ADCP)" refers to a cellular response in which antibodies bound to target cells bind to FcγRIIIa on the surface of macrophages, inducing macrophage activation, leading to internalization of the target cell and its degradation by phagosome acidification. ADCP can also be mediated by FcγRIIa and FcγRI, but to a lesser extent.

[0190] The term "complement-dependent cytotoxicity (CDC)" refers to the lysis of target cells in the presence of complement. The complement system is part of the innate immune system, consisting of a series of proteins. The proteins of the complement system are called "complement," represented by the abbreviations C1, C2, C3, etc. They are a group of heat-labile proteins present in human or vertebrate serum and tissue fluid that become enzymatically active upon activation. C1q is the first component of the complement-dependent cytotoxicity (CDC) pathway. It can bind six antibodies, but binding to two IgGs is sufficient to activate the complement cascade. Activation of the classical complement pathway is initiated by the binding of the first component of the complement system (C1q) to an antibody (of the appropriate subclass) that binds to the relevant antigen, activating a series of complement cascade reactions, forming pores in the target cell membrane, and leading to the death of the target cell. To assess complement activation, a CDC assay can be performed, for example, by the method described in Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996).

[0191] The term "variable region" or "variable domain" refers to the domain of an antibody heavy chain or light chain that is involved in binding the antibody to the antigen. The variable domains of the heavy and light chains of natural antibodies generally have similar structures, wherein each domain comprises four conserved framework regions (FRs) and three complementarity determining regions (CDRs). (See, e.g., Kindt et al., Kuby Immunology, 6 th ed., WH Freeman and Co. 91 p. (2007). A single VH or VL domain may be sufficient to confer antigen-binding specificity.

[0192] As used herein, the term "binding" or "specific binding" means that the binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antibody to bind to a specific antigen can be determined by enzyme-linked immunosorbent assay (ELISA), SPR or biofilm interferometry or other conventional binding assays known in the art.

[0193] The term "stimulation" refers to a primary response induced by the binding of a stimulatory molecule (e.g., a TCR / CD3 complex) to its corresponding ligand, which thereby mediates a signal transduction event, such as, but not limited to, signal transduction via the TCR / CD3 complex. Stimulation can mediate the expression of certain molecules, such as downregulation of TGF-β and / or reorganization of cytoskeletal structure.

[0194] The term "stimulatory molecule" refers to a molecule expressed by a T cell that provides a primary cytoplasmic signaling sequence that regulates the primary activation of the TCR complex in a stimulatory manner in at least some aspect of the T cell signaling pathway. In one embodiment, the primary signal is initiated, for example, by binding of the TCR / CD3 complex to a peptide-loaded MHC molecule and results in mediating a T cell response, including but not limited to proliferation, activation, differentiation, and the like. In the specific CARs of the present invention, the intracellular signaling domain in any one or more CARs of the present invention comprises an intracellular signaling sequence, for example, the primary signaling sequence of CD3ζ.

[0195] The term "CD3 ζ" is defined as a protein or its equivalent provided by GenBank accession number BAG36664.1, and "CD3 ζ stimulatory signaling domain" is defined as the amino acid residues from the cytoplasmic domain of the CD3 ζ chain that are sufficient to functionally propagate the initial signal necessary for T cell activation. In one embodiment, the cytoplasmic domain of CD3 ζ comprises residues 52 to residue 164 of GenBank accession number BAG36664.1 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.) that are functionally orthologous thereof. In one embodiment, the "CD3 ζ stimulatory signaling domain" is the sequence provided in SEQ ID NO: 17 or a variant thereof.

[0196] The term " costimulatory molecule " refers to the corresponding binding partner on the cell that specifically binds to the costimulatory reaction (such as but not limited to proliferation) of the costimulatory ligand so as to mediate the cell.Costimulatory molecules are cell surface molecules that contribute to effective immune response except antigen receptors or their ligands.Costimulatory molecules include but are not limited to MHC class I molecules, TNF receptor proteins, immunoglobulin-like proteins, cytokine receptors, integrins, signal transduction lymphocyte activation molecules (SLAM proteins), activation NK cell receptors, OX40, CD40, GITR, 4-1BB (i.e. CD137), CD27 and CD28. In some embodiments, " costimulatory molecule " is 4-1BB (i.e. CD137).Costimulatory signal domain refers to the intracellular part of costimulatory molecules.

[0197] The term "4-1BB" refers to a member of the TNFR superfamily having an amino acid sequence as provided in GenBank Accession No. AAA62478.2 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.); and "4-1BB costimulatory signaling domain" is defined as amino acid residues 214-255 of GenBank Accession No. AAA62478.2 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.). In one embodiment, the "4-1BB costimulatory domain" is a sequence as provided in SEQ ID NO: 16 or equivalent residues from non-human species (e.g., mice, rodents, monkeys, apes, etc.).

[0198] The term "signaling pathway" refers to the biochemical relationships between various signaling molecules that play a role in propagating a signal from one part of a cell to another part of the cell.

[0199] The term "cytokine" is a generic term for proteins released by one cell population that act as intercellular mediators on another cell. Examples of such cytokines include lymphokines, monokines, interleukins (ILs), such as IL-1, IL-1α, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, and IL-15; tumor necrosis factors, such as TNF-α and TNF-β; and other polypeptide factors, including interferon-γ.

[0200] An "isolated" antibody is one that has been separated from the components of its natural environment. In some embodiments, the antibodies of the invention are purified to greater than 95% or 99% purity, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatography (e.g., ion exchange or reversed-phase HPLC). For a review of methods for assessing antibody purity, see, e.g., Flatman et al., J. Chromatogr. B 848:79-87 (2007).

[0201] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location. An "isolated nucleic acid encoding an antibody of the invention" refers to one or more nucleic acid molecules that encode a chain of an antibody of the invention or a fragment thereof, including such nucleic acid molecules in a single vector or separate vectors, as well as such nucleic acid molecules present at one or more locations in a host cell.

[0202] Calculation of sequence identity between sequences is performed as follows.

[0203] To determine the percent identity of two amino acid sequences or two nucleic acid sequences, the sequences are aligned for optimal comparison purposes (e.g., gaps can be introduced in one or both of the first and second amino acid or nucleic acid sequences for optimal alignment or non-homologous sequences can be discarded for comparison purposes). In a preferred embodiment, for comparison purposes, the length of the reference sequence being aligned is at least 30%, preferably at least 40%, more preferably at least 50%, 60%, and even more preferably at least 70%, 80%, 90%, 100% of the length of the reference sequence. The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide at the corresponding position in the second sequence, then the molecules are identical at that position.

[0204] Mathematical algorithms can be used to compare sequences and calculate percent identity between two sequences. In a preferred embodiment, the percent identity between two amino acid sequences is determined using the Needlema and Wunsch ((1970) J. Mol. Biol. 48:444-453) algorithm (available at http: / / www.gcg.com), which has been integrated into the GAP program in the GCG software package. The Blossum 62 matrix or the PAM250 matrix is ​​used, and a gap weight of 16, 14, 12, 10, 8, 6, or 4 is used, and a length weight of 1, 2, 3, 4, 5, or 6 is used. In another preferred embodiment, the percent identity between two nucleotide sequences is determined using the GAP program in the GCG software package (available at http: / / www.gcg.com). A particularly preferred parameter set (and the one that should be used unless otherwise stated) is the Blossum 62 scoring matrix with a gap penalty of 12, a gap extension penalty of 4, and a frameshift gap penalty of 5.

[0205] The percent identity between two amino acid or nucleotide sequences can also be determined using the algorithm of E. Meyers and W. Miller, (1989) CABIOS, 4: 11-17), which has been incorporated into the ALIGN program (version 2.0), using a PAM120 weighted remainder table, a gap length penalty of 12, and a gap penalty of 4.

[0206] Additionally or alternatively, one can further use the nucleic acid sequences and protein sequences described herein as a "query sequence" to perform searches against public databases to, for example, identify other family member sequences or related sequences.

[0207] The terms "amino acid change" and "amino acid modification" are used interchangeably and refer to the addition, deletion, substitution and other modifications of amino acids. Any combination of amino acid addition, deletion, substitution and other modifications can be performed, provided that the final polypeptide sequence has the desired properties. In some embodiments, amino acid substitutions to antibodies result in reduced binding of the antibody to Fc receptors. For the purpose of changing, for example, the binding characteristics of the Fc region, non-conservative amino acid substitutions are particularly preferred, i.e., replacing one amino acid with another amino acid having different structural and / or chemical properties. Amino acid substitutions include substitutions with non-naturally occurring amino acids or naturally occurring amino acid derivatives of twenty standard amino acids (e.g., 4-hydroxyproline, 3-methylhistidine, ornithine, homoserine, 5-hydroxylysine). Amino acid changes can be produced using genetic or chemical methods well known in the art. Genetic methods can include site-directed mutagenesis, PCR, gene synthesis, etc. Methods for changing amino acid side chain groups by methods other than genetic engineering (e.g., chemical modification) may be useful. Various names can be used herein to represent the same amino acid changes. For example, a substitution from proline at position 329 of the Fc domain to glycine can be represented as 329G, G329, G 329 , P329G Pro329Gly, or simply "PG".

[0208] The terms "conservative sequence modifications" and "conservative sequence variations" refer to amino acid modifications or variations that do not significantly affect or alter the binding characteristics of the antibody or antibody fragment containing the amino acid sequence. Such conservative modifications include amino acid substitutions, additions, and deletions. Modifications can be introduced into the antibodies or antibody fragments of the present invention by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative substitutions are amino acid substitutions in which an amino acid residue is replaced by an amino acid residue with a similar side chain. Families of amino acid residues with similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), β-side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine). Thus, one or more amino acid residues within the CAR of the present invention can be replaced with other amino acid residues from the same side chain family, and the changed CAR can be tested using the functional assays described herein.

[0209] The term "autologous" refers to any substance that is derived from the same individual into whom the substance is later reintroduced.

[0210] The term "allogeneic" refers to any substance derived from an animal of the same species as the individual into which the substance is introduced. Two or more individuals are said to be allogeneic to one another when the genes at one or more loci are not identical. In some aspects, allogeneic substances from individuals of the same species can be sufficiently genetically dissimilar to interact antigenically.

[0211] The term "xenogeneic" refers to a graft derived from an animal of a different species.

[0212] As used herein, the term "apheresis" refers to an art-recognized in vitro method whereby blood from a donor or patient is removed from the donor or patient and passed through a device that separates selected specific components and returns the remainder to the donor's or patient's circulation, for example, by retransfusion. Thus, in the context of an "apheresis sample," a sample obtained using apheresis is referred to.

[0213] The term "immune effector cell" refers to a cell that participates in an immune response, e.g., participates in promoting an immune effector reaction. Examples of immune effector cells include T cells, e.g., α / β T cells and γ / δ T cells, B cells, natural killer (NK) cells, natural killer T (NKT) cells, mast cells, and myeloid-derived phagocytes.

[0214] "Immune effector function," "immune effector response," or "immune effector reaction" refers to, for example, a function or response of an immune effector cell that enhances or promotes immune attack on a target cell. For example, an immune effector function or response refers to a property of a T cell or NK cell that promotes killing of a target cell or inhibits growth or proliferation of a target cell. In the case of T cells, primary stimulation and co-stimulation are examples of immune effector functions or responses.

[0215] The term "effector function" refers to a specialized function of a cell. The effector function of a T cell may be, for example, cytolytic activity or helper activity, including the secretion of cytokines.

[0216] The term "T cell activation" refers to one or more cellular responses of T lymphocytes, particularly cytotoxic T lymphocytes, selected from the group consisting of proliferation, differentiation, cytokine secretion, release of cytotoxic effector molecules, cytotoxic activity, and expression of activation markers. The chimeric antigen receptors of the present invention are capable of inducing T cell activation. Suitable assays for measuring T cell activation are described in the Examples and are known in the art.

[0217] The term "lentivirus" refers to a genus of the Retroviridae family. Lentiviruses are unique among retroviruses in their ability to infect non-dividing cells; they can deliver significant amounts of genetic information to host cells, making them one of the most efficient gene delivery vectors. HIV, SIV, and FIV are all examples of lentiviruses.

[0218] The term "lentiviral vector" refers to a vector derived from at least a portion of a lentiviral genome, and particularly includes self-inactivating lentiviral vectors as provided in Milone et al., Mol. Ther. 17(8): 1453–1464 (2009). Other examples of lentiviral vectors that can be used clinically include, but are not limited to, those from Oxford BioMedica. Gene delivery technology, LENTIMAX from Lentigen TM Vector systems, etc. Non-clinical types of lentiviral vectors are also available and known to those skilled in the art.

[0219] The term "BCMA-associated disease" refers to any condition caused by, exacerbated by, or otherwise associated with increased expression or activity of BCMA.

[0220] The terms "individual" or "subject" are used interchangeably and include mammals. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In particular, the individual or subject is a human.

[0221] The terms "tumor" and "cancer" are used interchangeably herein to encompass both solid and liquid tumors.

[0222] The terms "cancer" and "cancerous" refer to the physiological condition in mammals characterized by unregulated cell growth.

[0223] The term "tumor" refers to all neoplastic cell growth and proliferation, whether malignant or benign, and all precancerous and cancerous cells and tissues. The terms "cancer," "cancerous," and "tumor" are not mutually exclusive when referred to herein.

[0224] "Tumor immune escape" refers to the process by which a tumor evades immune recognition and clearance. Thus, as a therapeutic concept, tumor immunity is "treated" when this evasion is compromised, allowing the tumor to be recognized and attacked by the immune system. Examples of tumor recognition include tumor binding, tumor shrinkage, and tumor clearance.

[0225] The term "median effective concentration (EC50) 50)" refers to the concentration of drug, antibody or toxic agent that induces a response that is 50% between baseline and maximum after a specified exposure time.

[0226] The term "fluorescence activated cell sorting" or "FACS" refers to a specialized type of flow cytometry. It provides a method for sorting a heterogeneous mixture of biological cells into two or more containers one cell at a time based on the specific light scattering and fluorescence characteristics of each cell (FlowMetric. "Sorting Out Fluorescence Activated Cell Sorting". 2017-11-09). Instruments for performing FACS are known to those skilled in the art and are commercially available to the public. Examples of such instruments include the FACS Star Plus, FACScan, and FACSort instruments from Becton Dickinson (Foster City, CA), the Epics C from Coulter Epics Division (Hialeah, FL), and the MoFlo from Cytomation (Colorado Springs, Colorado).

[0227] The term "pharmaceutically acceptable excipient" refers to a diluent, adjuvant (eg, Freund's adjuvant (complete and incomplete)), excipient, buffer, stabilizer, or the like, which is administered together with the active substance.

[0228] As used herein, "treat" refers to slowing, interrupting, retarding, alleviating, stopping, reducing, or reversing the progression or severity of an existing symptom, disorder, condition, or disease. Desired therapeutic effects include, but are not limited to, preventing the onset or recurrence of a disease, alleviating symptoms, reducing any direct or indirect pathological consequences of a disease, preventing metastasis, reducing the rate of disease progression, ameliorating or alleviating the disease state, and alleviating or improving prognosis. In some embodiments, the antibody molecules of the present invention are used to delay disease progression or to slow the progression of a disease.

[0229] The term "effective amount" refers to an amount or dosage of an antibody or composition of the present invention that produces the desired effect in a patient in need of treatment or prevention after administration to the patient in a single or multiple doses. The effective amount can be readily determined by the attending physician, who is skilled in the art, by considering a variety of factors such as the species of the mammal; weight, age, and general health; the specific disease involved; the extent or severity of the disease; the response of the individual patient; the specific antibody administered; the mode of administration; the bioavailability characteristics of the administered formulation; the selected dosing regimen; and the use of any concomitant therapy.

[0230] A "therapeutically effective amount" refers to an amount effective to achieve the desired therapeutic outcome at the desired dosage and for the desired period of time. A therapeutically effective amount of an antibody or antibody fragment or composition thereof can vary depending on a variety of factors, such as the disease state, age, sex, and weight of the individual, and the ability of the antibody or antibody portion to elicit a desired response in the individual. A therapeutically effective amount is also an amount in which any toxic or deleterious effects of the antibody or antibody fragment or composition thereof are outweighed by the therapeutically beneficial effects. A "therapeutically effective amount" preferably inhibits a measurable parameter (e.g., tumor growth rate, tumor volume, etc.) by at least about 20%, more preferably at least about 40%, even more preferably at least about 50%, 60%, or 70%, and still more preferably at least about 80% or 90% relative to an untreated subject. The ability of a compound to inhibit a measurable parameter (e.g., cancer) can be evaluated in an animal model system that is predictive of efficacy in human tumors.

[0231] The term "drug combination" or "drug combination product" refers to a non-fixed combination (product) or a fixed combination (product), including but not limited to a drug box. The term "non-fixed combination" means that the active ingredients (e.g., (i) P329G CAR-T cells and (ii) P329G mutant antibodies for BCMA) are administered to the subject simultaneously, without specific time restrictions or at the same or different time intervals, in sequence as separate entities, wherein such administration provides effective treatment in the subject. The term "fixed combination" refers to a combination of P329G mutant antibodies for BCMA and P329G CAR-T cells of the present invention, each of which is administered to the patient simultaneously in the form of a specific single dose. The term "non-fixed combination" means that the combination of 329G mutant antibodies for BCMA and P329G CAR-T cells of the present invention is administered to the patient simultaneously, in parallel or in sequence as separate entities, without specific dosage and time restrictions, wherein such administration provides a therapeutically effective level of the drug combination of the present invention in the patient's body. In a preferred embodiment, the drug combination is a non-fixed combination.

[0232] The term "vector," as used herein when referring to nucleic acids, refers to a nucleic acid molecule that is capable of propagating another nucleic acid to which it is attached. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which they have been introduced. Some vectors are capable of directing the expression of nucleic acids to which they are operatively attached. Such vectors are referred to herein as "expression vectors."

[0233] The term "host cell" refers to a cell into which an exogenous polynucleotide has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells", which include primary transformed cells and progeny derived therefrom, without considering the number of passages. Progeny may not be completely identical to the parent cell in nucleic acid content, but may contain mutations. Included herein are mutant progeny with the same function or biological activity that have been screened or selected in the initially transformed cells. Host cells are any type of cell system that can be used to produce the antibody molecules of the present invention, including eukaryotic cells, for example, mammalian cells, insect cells, yeast cells; and prokaryotic cells, for example, Escherichia coli cells. Host cells include cultured cells, as well as cells within transgenic animals, transgenic plants, or cultured plant tissues or animal tissues.

[0234] "Subject / patient sample" refers to a collection of cells, tissues, or body fluids obtained from a patient or subject. The source of the tissue or cell sample can be a solid tissue, such as an organ or tissue sample or a biopsy sample or a puncture sample from a fresh, frozen, and / or preserved organ or tissue sample; blood or any blood component; body fluids, such as cerebrospinal fluid, amniotic fluid (amniotic fluid), peritoneal fluid (ascites), or interstitial fluid; cells from any time during the subject's pregnancy or development. Tissue samples may contain compounds that are not naturally mixed with tissues in nature, such as preservatives, anticoagulants, buffers, fixatives, nutrients, antibiotics, and the like. Examples of tumor samples herein include, but are not limited to, tumor biopsies, fine needle aspirates, bronchial lavage fluid, pleural fluid (pleural effusion), sputum, urine, surgical specimens, circulating tumor cells, serum, plasma, circulating plasma proteins, ascites, primary cell cultures or cell lines derived from tumors or exhibiting tumor-like properties, and preserved tumor samples, such as formalin-fixed, paraffin-embedded tumor samples or frozen tumor samples.

[0235] The term "treat" with reference to a disease means to alleviate the disease (ie, slow or arrest or reduce the development of the disease or at least one clinical symptom thereof), prevent or delay the onset or development or progression of the disease.

[0236] II. Molecular switch-regulated chimeric antigen receptor (CAR) of the present invention

[0237] The present invention relates to chimeric antigen receptor polypeptides capable of specifically binding to a mutant Fc domain of an antibody against a BCMA molecule. Specifically, the chimeric antigen receptor of the present invention comprises a humanized anti-P329G mutant scFv sequence, and the scFv sequence is capable of specifically binding to an antibody Fc domain comprising a P329G mutation, but is unable to specifically bind to an unmutated parent antibody Fc domain. Compared to the binding of the unmutated parent antibody Fc domain to the Fc receptor, the binding of the antibody Fc domain comprising the P329G mutation to an Fc receptor (e.g., an Fcγ receptor) is reduced.

[0238] The recombinant CAR construct of the present invention comprises a sequence encoding CAR, wherein the CAR comprises a humanized anti-P329G mutation scFv sequence, and the scFv sequence specifically binds to the antibody Fc domain of the P329G mutation.

[0239] In one embodiment, the scFv sequence in the CAR construct of the present invention comprises the following sequence:

[0240] (i) a heavy chain variable region comprising a

[0241] (a) a heavy chain complementarity determining region CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 19), or a variant of said CDR H1 having no more than two amino acid changes or no more than one amino acid change;

[0242] (b) CDR H2 shown in the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 20), or a variant of said CDR H2 with no more than 2 amino acid changes or no more than 1 amino acid change; and

[0243] (c) CDR H3 represented by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 21), or a variant of said CDR H3 having no more than two amino acid changes or no more than one amino acid change; and

[0244] (ii) a light chain variable region comprising a

[0245] (d) a light chain complementarity determining region (CDR L) 1 represented by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 22), or a variant of said CDR L1 having no more than two amino acid changes or no more than one amino acid change;

[0246] (e) CDR L2 shown in the amino acid sequence GTNCRAP (SEQ ID NO: 23), or a variant of said CDR L2 with no more than 2 amino acid changes or no more than 1 amino acid change; and

[0247] (f) CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 24), or a variant of said CDR L3 having no more than two amino acid changes or no more than one amino acid change;

[0248] The amino acid change is an addition, deletion or substitution of an amino acid.

[0249] Further, the scFv can be linked to a signal peptide sequence at the N-terminus, for example, the signal peptide sequence shown in SEQ ID NO: 11, and the scFv can be linked to an optional hinge / spacer sequence as provided in SEQ ID NO: 14 or SEQ ID NO: 18, a transmembrane region as provided in SEQ ID NO: 15, a costimulatory signaling domain as provided in SEQ ID NO: 16, and an intracellular stimulatory signaling domain comprising SEQ ID NO: 17 or a variant thereof at the C-terminus, for example, wherein the respective domains are adjacent to each other and are in the same reading frame to form a single fusion protein.

[0250] In some embodiments, the scFv domain comprises (i) a heavy chain variable region comprising a sequence of SEQ ID NO: 12, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, and (ii) a light chain variable region comprising a sequence of SEQ ID NO: 13, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto;

[0251] In some embodiments, the scFv domain comprises (i) a heavy chain variable region set forth in SEQ ID NO: 12 and (ii) a light chain variable region set forth in SEQ ID NO: 13. In one embodiment, the scFv domain further comprises a (Gly4-Ser)n linker, wherein n is 1, 2, 3, 4, 5, or 6, preferably 3 or 4. The light chain variable region and the heavy chain variable region of the scFv can be, for example, in any of the following orientations: light chain variable region-linker-heavy chain variable region or heavy chain variable region-linker-light chain variable region.

[0252] In some embodiments, an exemplary CAR construct of the present invention comprises a signal peptide sequence, a humanized anti-P329G mutant scFv sequence, a hinge region / spacer, a transmembrane domain, an intracellular co-stimulatory signaling domain, and an intracellular stimulatory signaling domain.

[0253] In one embodiment, the present invention provides the amino acid sequence of the full-length CAR polypeptide as SEQ ID NO: 1, as shown in the sequence listing.

[0254] In some embodiments, the present invention provides a recombinant nucleic acid construct comprising a nucleic acid molecule encoding a CAR of the present invention, for example, comprising a nucleic acid molecule encoding an amino acid sequence shown in SEQ ID NO: 1 or an amino acid sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO: 1. The CAR construct encoding the present invention can be obtained using recombinant methods well known in the art. Alternatively, the target nucleic acid can be produced synthetically rather than by genetic recombination methods.

[0255] The present invention includes retroviral and lentiviral vector constructs that express CARs that can be directly transduced into cells.

[0256] In some embodiments, the nucleic acid sequence of the CAR construct of the present invention is cloned into a lentiviral vector to generate a full-length CAR construct in a single coding frame, and the EF1α promoter is used for expression.

[0257] It will be understood by those of ordinary skill in the art that the CAR polypeptides of the present invention can also be modified so as to change in the amino acid sequence, but not in terms of the desired activity. For example, the CAR polypeptide can be subjected to additional nucleotide substitutions that result in amino acid substitutions at "non-essential" amino acid residues. For example, the non-essential amino acid residue in the molecule can be replaced with another amino acid residue from the same side chain family. In another embodiment, an amino acid fragment can be replaced with a structurally similar fragment that differs in the order and composition of the side chain family members, for example, a conservative substitution can be performed in which the amino acid residue is replaced with an amino acid residue having a similar side chain.

[0258] Families of amino acid residues having similar side chains have been defined in the art, including basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine), nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan), beta-branched side chains (e.g., threonine, valine, isoleucine), and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan, histidine).

[0259] In some embodiments, the present invention contemplates the generation of functionally equivalent CAR polypeptide molecules, for example, the VH or VL of the humanized anti-P329G mutant scFv sequence contained in the CAR can be modified to obtain a VH having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 12 and a VL having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity with SEQ ID NO: 13.

[0260] The membrane spaning domain included in the CAR of the present invention is an anchored membrane spaning domain, which is a component of a polypeptide chain that can be integrated into a cell membrane. The membrane spaning domain can be fused with other extracellular and / or intracellular polypeptide domains, wherein these extracellular and / or intracellular polypeptide domains will also be restricted to the cell membrane. In the chimeric antigen receptor (CAR) polypeptide of the present invention, the membrane spaning domain confers the membrane attachment of the CAR polypeptide of the present invention. The CAR polypeptide of the present invention includes at least one membrane spaning domain, which can be derived from a natural source or a recombinant source, including advantageous hydrophobic residues such as leucine and valine. In the case where the source is natural, the domain can be derived from a membrane-bound protein or a membrane spaning protein such as CD28, CD8 (e.g., CD8α, CD8β) membrane spaning domain. In one embodiment, the membrane spaning domain includes SEQ ID NO:15 amino acid sequence.

[0261] In some embodiments, the transmembrane domain in the CAR of the present invention is connected to the extracellular region of CAR (i.e., humanized anti-P329G mutant scFv sequence) by means of a hinge region / spacer. For example, in one embodiment, the hinge can be a hinge region of CD8α, CD28. In some embodiments, the hinge region or spacer sequence comprises the amino acid sequence of SEQ ID NO: 18.

[0262] Additionally, glycine-serine doublets also provide particularly suitable linkers as hinge / spacer regions. For example, in one embodiment, the linker comprises the amino acid sequence of GGGGS (SEQ ID NO: 14).

[0263] The cytoplasmic domain included in the CAR of the present invention includes an intracellular signaling domain. The intracellular signaling domain can activate at least one effector function of the immune cell introduced with the CAR of the present invention.

[0264] Examples of intracellular signaling domains for use in the CARs of the present invention include cytoplasmic sequences of T cell receptors (TCRs) and co-receptors that act synergistically to initiate signal transduction after the extracellular domain binds to the P329G mutated antibody Fc domain, as well as any derivatives or variants of these sequences and any recombinant sequences with the same functional capacity.

[0265] Considering that the signal generated by TCR alone is not enough to fully activate T cells, the CAR of the present invention is also designed to generate a costimulatory signal domain (CSD). The activation of T cells is mediated by two different types of cytoplasmic signaling sequences: those sequences that initiate antigen-dependent primary activation by TCR (primary intracellular signaling domains) and those sequences that act in an antigen-independent manner to provide costimulatory signals (secondary cytoplasmic domains, e.g., costimulatory domains).

[0266] In one embodiment, the CAR of the present invention comprises a primary intracellular signaling domain, e.g., a primary signaling domain of CD3ζ, e.g., a CD3ζ signaling domain set forth in SEQ ID NO: 17.

[0267] The intracellular signaling domain in the CAR of the present invention also includes a secondary signaling domain (ie, a costimulatory signaling domain). The costimulatory signaling domain refers to the CAR portion of the intracellular domain comprising a costimulatory molecule. Costimulatory molecules are cell surface molecules required for lymphocytes to effectively respond to antigens in addition to antigen receptors or their ligands. In some embodiments, costimulatory molecules include but are not limited to CD28, 4-1BB (CD137), and the costimulatory effect caused by them enhances the proliferation, effector function and survival of human CART cells in vitro and promotes the anti-tumor activity of human T cells in vivo.

[0268] Intracellular signaling sequences of the CAR of the present invention can be connected to each other in a random order or in a specified order. Optionally, a short oligopeptide linker or a polypeptide linker can form a bond between intracellular signaling sequences. In one embodiment, a glycine-serine doublet can be used as a suitable linker. In one embodiment, a single amino acid, e.g., alanine, glycine, can be used as a suitable linker.

[0269] In one embodiment, the intracellular signaling domain of the CAR of the present invention is designed to include the costimulatory signaling domain of 4-1BB and the stimulatory signaling domain of CD3ζ.

[0270] III. Nucleic acid molecules encoding the CAR of the present invention, vectors, and cells expressing the CAR of the present invention

[0271] The present invention provides nucleic acid molecules encoding CAR constructs described herein.In one embodiment, the nucleic acid molecule is provided as a DNA construct.

[0272] The present invention also provides a vector having a CAR construct of the present invention inserted therein. By effectively connecting the nucleic acid encoding the CAR polypeptide to a promoter and incorporating the construct into an expression vector, the expression of the natural or synthetic nucleic acid encoding the CAR is achieved. The vector may be suitable for replication and integration in eukaryotic organisms. Common cloning vectors contain transcription and translation terminators, initiation sequences, and promoters for regulating the expression of the desired nucleic acid sequence.

[0273] Numerous virus-based systems have been developed for transferring genes into mammalian cells. For example, retroviruses provide a convenient platform for gene delivery systems. The selected gene can be inserted into a vector and packaged into retroviral particles using techniques known in the art. The recombinant virus can then be isolated and delivered to the subject's cells in vivo or ex vivo. Numerous retroviral systems are known in the art. In some embodiments, lentiviral vectors are used.

[0274] Vectors derived from retroviruses (such as slow viruses) are suitable tools for achieving long-term gene transfer because they allow long-term, stable integration of transgenics and their propagation in daughter cells. Slow virus vectors have the additional advantage of being better than vectors derived from cancer-retroviruses (such as murine leukemia viruses) because they can transduce non-proliferative cells, such as hepatocytes. They also have additional low immunogenicity advantages. Retroviral vectors can also be, for example, γ retroviral vectors. γ retroviral vectors can, for example, include promoters, packaging signals (ψ), primer binding sites (PBS), one or more (for example, two) long terminal repeats (LTR) and target transgenics, for example, genes encoding CAR. γ retroviral vectors can lack viral structural genes such as gag, pol and env.

[0275] An example of a promoter capable of expressing a CAR transgene in mammalian T cells is the EF1a promoter. The natural EF1a promoter drives the expression of the α subunit of the elongation factor-1 complex, which is responsible for enzymatic delivery of aminoacyl tRNA to the ribosome. The EF1a promoter has been widely used in mammalian expression plasmids and has been shown to effectively drive the expression of CAR from a transgene cloned into a lentiviral vector. See, for example, Milone et al., Mol. Ther. 17 (8): 1453–1464 (2009).

[0276] Another example of a promoter is the immediate early cytomegalovirus (CMV) promoter sequence. This promoter sequence is a strong constitutive promoter sequence that can drive any polynucleotide sequence effectively connected thereto for high-level expression. However, other constitutive promoter sequences may also be used, including but not limited to simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), human immunodeficiency virus (HIV) long terminal repeat (LTR) promoter, MoMuLV promoter, avian leukemia virus promoter, Epstein-Barr virus immediate early promoter, Rous sarcoma virus promoter, and human gene promoters, such as but not limited to actin promoter, myosin promoter, elongation factor-1α promoter, hemoglobin promoter, and creatine kinase promoter. In addition, the present invention should not be limited to the use of constitutive promoters. Inducible promoters have also been contemplated as part of the present invention.

[0277] In some embodiments, the present invention provides methods of expressing a CAR construct of the invention in a mammalian immune effector cell (e.g., a mammalian T cell or a mammalian NK cell) and the immune effector cells produced thereby.

[0278] Cell sources (e.g., immune effector cells, e.g., T cells or NK cells) are obtained from a subject. The term "subject" is intended to include living organisms (e.g., mammals) that can stimulate an immune response. T cells can be obtained from numerous sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from an infection site, ascites, pleural effusion, spleen tissue, and tumors.

[0279] Can use any technology known to those skilled in the art (such as FicollTM separation method), from collecting from experimenter's blood component, obtain T cell.In a preferred aspect, obtain the cell from individual circulating blood by single blood component technique.Single blood component product generally contains lymphocyte, comprises T cell, monocyte, granulocyte, B cell, other nucleated leukocyte, erythrocyte and platelet.In one embodiment, can wash the cell that single blood component technique collects, to remove plasma fraction and to place cell in suitable buffer or culture medium for subsequent processing step.In one aspect of the invention, use phosphate buffered saline (PBS) (PBS) washing cell.

[0280] Specific T cell subsets, such as CD3+, CD28+, CD4+, CD8+, CD45RA+, and CD45RO+ T cells, can be further isolated by positive or negative selection techniques. For example, in one embodiment, the T cells are isolated by beads conjugated with anti-CD3 / anti-CD28 (e.g., In some embodiments, the time period is between about 30 minutes and 36 hours or longer. Longer incubation times can be used to separate T cells in the presence of a small amount of T cells, such as for separating tumor infiltrating lymphocytes (TIL) from tumor tissue or from immunocompromised individuals. In addition, longer incubation times can be used to increase the efficiency of capturing CD8+ T cells. Therefore, by simply shortening or extending the time, allowing T cells to combine with CD3 / CD28 beads and / or by increasing or reducing the ratio of beads to T cells, T cell subsets can be selected preferentially at other time points at the beginning of cultivation or during the culture process.

[0281] Enrichment of T cell populations can be accomplished by a negative selection process using a combination of antibodies directed against surface markers unique to the negatively selected cells. One approach is to sort and / or select cells using negative magnetic immunoadhesion or flow cytometry using a cocktail of monoclonal antibodies directed against cell surface markers present on the negatively selected cells.

[0282] In some embodiments, immune effector cell can be an allogeneic immune effector cell, for example, a T cell or a NK cell. For example, the cell can be an allogeneic T cell, for example, an allogeneic T cell lacking a functional T cell receptor (TCR) and / or human leukocyte antigen (HLA) (for example, HLA class I and / or HLA class II) expression.

[0283] A T cell lacking a functional TCR can, for example, be engineered so that it does not express any functional TCR on its surface; engineered so that it does not express one or more subunits that make up a functional TCR (e.g., engineered so that it does not express or exhibits reduced expression of TCRα, TCRβ, TCRγ, TCRδ, TCRε and / or TCRζ); or engineered so that it produces very few functional TCRs on its surface.

[0284] The T cells described herein can be engineered, for example, so that they do not express functional HLA on their surface. For example, the T cells described herein can be engineered so that cell surface expression of HLA (e.g., HLA class I and / or HLA class II) is downregulated. In some aspects, downregulation of HLA can be achieved by reducing or eliminating beta-2 microglobulin (B2M) expression.

[0285] In some embodiments, the T cell may lack a functional TCR and a functional HLA, e.g., HLA class I and / or HLA class II.

[0286] In one embodiment, cells transduced with a nucleic acid encoding a CAR of the invention are proliferated, for example, the cells are proliferated in culture for 2 hours to about 14 days.

[0287] The CAR-expressing immune effector cells obtained after in vitro proliferation can be tested for effector function as described in the examples.

[0288] In a specific embodiment, the first component suitable for use in the pharmaceutical combination of the present invention is a CAR-T cell comprising the CAR of the present invention.

[0289] IV. Antibodies that Specifically Bind to BCMA Molecules and Antibodies Comprising Mutated Fc Domains

[0290] The present invention provides an antibody that binds to BCMA with high target specificity and high affinity, comprising a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises a CDR H1 set forth in the amino acid sequence SSSYYWT (SEQ ID NO: 25) according to Kabat numbering, or a variant of the CDR H1 with no more than 2 amino acid changes or no more than 1 amino acid change; a CDR H2 set forth in the amino acid sequence SISIAGSTYYNPSLKS (SEQ ID NO: 26), or a variant of the CDR H2 with no more than 2 amino acid changes or no more than 1 amino acid change; and a CDR H3 set forth in the amino acid sequence DRGDQILDV (SEQ ID NO: 27), or a variant of the CDR H3 with no more than 2 amino acid changes or no more than 1 amino acid change; the light chain variable region comprises a CDR L1 set forth in the amino acid sequence RASQSISRYLN (SEQ ID NO: 28) according to Kabat numbering, or a variant of the CDR L1 with no more than 2 amino acid changes or no more than 1 amino acid change; a CDR L2, or a variant of said CDR L2 with no more than 2 amino acid changes or no more than 1 amino acid change; and CDR L3 set forth in the amino acid sequence QQKYFDIT (SEQ ID NO: 30), or a variant of said CDR L3 with no more than 2 amino acid changes or no more than 1 amino acid change;

[0291] The amino acid changes are amino acid additions, deletions or conservative amino acid substitutions.

[0292] In some embodiments, the antibodies of the invention that bind to BCMA molecules bind to mammalian BCMA, such as human, cynomolgus monkey, mouse, rat, and rabbit BCMA.

[0293] In some embodiments, the antibodies of the present invention that bind to BCMA molecules have one or more of the following properties:

[0294] (1) Specific binding to BCMA;

[0295] (2) binds to human BCMA and cross-reacts with cynomolgus monkey, mouse, rat, and rabbit BCMA;

[0296] (3) In the absence of a mutant Fc domain, for example, in the case of having an unmutated parental antibody Fc domain, BCMA-positive cancer cells can be killed by antibody-dependent cellular cytotoxicity and / or antibody-dependent cellular phagocytosis (ADCP).

[0297] In some embodiments, an antibody that binds to a BCMA molecule of the present invention comprises a heavy chain variable region, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 2, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, wherein the amino acid changes in the sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity are preferably amino acid substitutions, more preferably conservative amino acid substitutions, and preferably, the amino acid changes do not occur in the CDR regions.

[0298] In some embodiments, an antibody that binds to a BCMA molecule of the present invention comprises a light chain variable region, wherein the light chain variable region comprises the sequence of SEQ ID NO: 3, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, wherein the amino acid changes in the sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity are preferably amino acid substitutions, more preferably conservative amino acid substitutions, and preferably, the amino acid changes do not occur in the CDR regions.

[0299] In some embodiments, an antibody that binds to a BCMA molecule of the invention comprises a heavy chain variable region and a light chain variable region, wherein:

[0300] the heavy chain variable region comprises a sequence of SEQ ID NO: 2, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, and the light chain variable region comprises a sequence of SEQ ID NO: 3, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto;

[0301] The amino acid changes in the sequences with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity are preferably amino acid substitutions, more preferably conservative amino acid substitutions, and preferably, the amino acid changes do not occur in the CDR regions.

[0302] In some embodiments, an antibody that binds to a BCMA molecule of the present invention comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises or consists of the sequence of SEQ ID NO: 2, and the light chain variable region comprises or consists of the sequence of SEQ ID NO: 3.

[0303] In some embodiments, the antibody of the present invention that binds to a BCMA molecule is an IgG1, IgG2, IgG3, or IgG4 antibody; preferably, it is an IgG1 or IgG4 antibody; more preferably, it is an IgG1 antibody, for example, a human IgG1 antibody.

[0304] In some embodiments, an antibody that binds to a BCMA molecule provided herein comprises a mutant Fc domain, wherein the amino acid at position P329 according to EU numbering is mutated to glycine (G), and the Fcγ receptor binding of the mutant Fc domain is reduced compared to the Fcγ receptor binding of the unmutated parent antibody Fc domain; for example, the mutant Fc domain is a mutant Fc domain of an IgG1, IgG2, IgG3, or IgG4 antibody, preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 or IgG4 antibody; more preferably, the mutant Fc domain is a mutant Fc domain of an IgG1 antibody, for example, the mutant Fc domain is a mutant Fc domain of a human IgG1 antibody. In some embodiments, the mutant Fc domain comprises the amino acid sequence of SEQ ID NO: 10, or has at least 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% sequence identity thereto, and comprises a P329G mutation.

[0305] In some embodiments, the antibody that binds to a BCMA molecule comprising a P329G mutant Fc domain is incapable of antibody-dependent cellular cytotoxicity by binding to Fcγ receptors, and is incapable of antibody-dependent cellular phagocytosis (ADCP).

[0306] In some embodiments, an antibody that binds to a BCMA molecule of the invention comprises a heavy chain, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 34, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto and comprises P329G (EU numbering), wherein the amino acid change in the sequence of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity is preferably an amino acid substitution, more preferably a conservative amino acid substitution, and preferably, the amino acid change does not occur in a CDR region or in the variable region.

[0307] In some embodiments, an antibody that binds to a BCMA molecule of the invention comprises a light chain, wherein the light chain variable region comprises the sequence of SEQ ID NO: 35, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, wherein the amino acid changes in the sequence with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity are preferably amino acid substitutions, more preferably conservative amino acid substitutions, and preferably, the amino acid changes do not occur in the CDR regions or in the variable region.

[0308] In some embodiments, an antibody that binds to a BCMA molecule of the invention comprises a heavy chain and a light chain, wherein:

[0309] the heavy chain comprises the sequence of SEQ ID NO:34, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto, and the light chain comprises the sequence of SEQ ID NO:35, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto;

[0310] The amino acid changes in the sequences of at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity are preferably amino acid substitutions, more preferably conservative amino acid substitutions, and preferably, the amino acid changes do not occur in the CDR regions or the variable regions.

[0311] In some embodiments, an antibody that binds to a BCMA molecule of the invention comprises a heavy chain and a light chain, wherein the heavy chain comprises or consists of the sequence of SEQ ID NO: 34, and the light chain comprises or consists of the sequence of SEQ ID NO: 35.

[0312] In some embodiments, the present invention provides nucleic acids encoding any of the above antibodies or fragments thereof or any of their chains that bind to a BCMA molecule. In one embodiment, a vector comprising the nucleic acid is provided. In one embodiment, the vector is an expression vector. In one embodiment, a host cell comprising the nucleic acid or the vector is provided. In one embodiment, the host cell is eukaryotic. In another embodiment, the host cell is selected from yeast cells, mammalian cells (e.g., CHO cells or 293 cells), or other cells suitable for preparing antibodies or antigen-binding fragments thereof. In another embodiment, the host cell is prokaryotic.

[0313] For example, the nucleic acids of the present invention include nucleic acids encoding antibodies that bind to BCMA molecules of the present invention. In some embodiments, one or more vectors comprising the nucleic acids are provided. In one embodiment, the vector is an expression vector, such as a eukaryotic expression vector. Vectors include, but are not limited to, viruses, plasmids, cosmids, lambda phages, or yeast artificial chromosomes (YACs). In one embodiment, the vector is a pcDNA3.4 expression vector.

[0314] Once an expression vector or DNA sequence for expression has been prepared, the expression vector can be transfected or introduced into a suitable host cell. A variety of techniques can be used to achieve this purpose, for example, protoplast fusion, calcium phosphate precipitation, electroporation, retroviral transduction, viral transfection, gene gun, lipid-based transfection or other conventional techniques. In the case of protoplast fusion, the cells are cultivated in culture medium and screened for suitable activity. Methods and conditions for cultivating the transfected cells produced and for recovering the antibody molecules produced are known to those skilled in the art and can be based on this specification and methods known in the prior art, according to the specific expression vector and mammalian host cell used, change or optimize.

[0315] In addition, can allow to select one or more markers of transfected host cell by introducing, select the cell that stablizes DNA and is incorporated into its chromosome.Marker can for example provide prototrophy, biocidal resistance (for example, antibiotic) or heavy metal (such as copper) resistance etc. to auxotrophic host.Selectable marker gene can be directly connected with dna sequence dna to be expressed or be introduced into identical cell by cotransformation.Also may need extra element so that best synthetic mRNA.These elements can comprise splicing signal, and transcription promoter, enhancer and termination signal.

[0316] In one embodiment, a host cell comprising a polynucleotide of the present invention is provided. In some embodiments, a host cell comprising an expression vector of the present invention is provided. In some embodiments, the host cell is selected from yeast cells, mammalian cells, or other cells suitable for preparing antibodies. Suitable host cells include prokaryotic microorganisms, such as Escherichia coli. The host cell can also be a eukaryotic microorganism such as a filamentous fungus or yeast, or various eukaryotic cells, such as insect cells. Vertebrate cells can also be used as hosts. For example, a mammalian cell line modified to be suitable for suspension growth can be used. Examples of useful mammalian host cell lines include SV40-transformed monkey kidney CV1 line (COS-7); human embryonic kidney line (HEK293 or 293F cells), 293 cells, baby hamster kidney cells (BHK), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), Buffalo rat liver cells (BRL 3A), human lung cells (W138), human liver cells (HepG2), Chinese hamster ovary cells (CHO cells), CHO-S cells, NSO cells, myeloma cell lines such as Y0, NSO, P3X63 and Sp2 / 0, etc. For a review of mammalian host cell lines suitable for protein production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo ed., Humana Press, Totowa, NJ), pp. 255-268 (2003). In a preferred embodiment, the host cell is a CHO cell or a HEK293 cell.

[0317] In one embodiment, the present invention provides a method for preparing an antibody that binds to a BCMA molecule (including a P329G mutant antibody), wherein the method comprises culturing a host cell containing a nucleic acid encoding the antibody that binds to a BCMA molecule (including a P329G mutant antibody) or an expression vector containing the nucleic acid under conditions suitable for expressing the nucleic acid encoding the antibody that binds to a BCMA molecule (including a P329G mutant antibody), and optionally isolating the antibody that binds to a BCMA molecule (including a P329G mutant antibody). In a certain embodiment, the method further comprises recovering the antibody that binds to a BCMA molecule (including a P329G mutant antibody) from the host cell (or host cell culture medium).

[0318] Antibodies that bind to BCMA molecules of the present invention (including P329G mutant antibodies) prepared as described herein can be purified by known techniques such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, and the like. The actual conditions used to purify a particular protein will also depend on factors such as net charge, hydrophobicity, and hydrophilicity, and these will be apparent to those skilled in the art. The purity of antibodies that bind to BCMA molecules of the present invention (including P329G mutant antibodies) can be determined by any of a variety of well-known analytical methods, including size exclusion chromatography, gel electrophoresis, high performance liquid chromatography, and the like.

[0319] The antibodies (including P329G mutant antibodies) that bind to BCMA molecules provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activity by a variety of assays known in the art. On the one hand, the antibodies (including P329G mutant antibodies) that bind to BCMA molecules of the present invention are tested for their antigen binding activity, for example, by known methods such as FACS, ELISA, or Western blotting. Binding to BCMA can be determined using methods known in the art, and exemplary methods are disclosed herein. In some embodiments, FACS is used to determine the binding of antibodies (including P329G mutant antibodies) that bind to BCMA molecules of the present invention to cell surface BCMA (eg, human BCMA).

[0320] The present invention also provides an assay for identifying antibodies (including P329G mutant antibodies) that bind to BCMA molecules and have biological activity. Biological activity can include, for example, ADCC effect, CDC effect, etc.

[0321] Cells used in any of the above in vitro assays include cell lines that naturally express BCMA or are engineered to express BCMA. The cell lines engineered to express BCMA are cell lines that do not normally express BCMA but express BCMA after transfection of BCMA-encoding DNA into the cells.

[0322] V. Pharmaceutical Combinations of the Present Invention

[0323] For optimizing the safety and efficacy of CAR therapy, the molecular switch regulated chimeric antigen receptor of the present invention is a regulatable CAR that can control the activity of CAR. The present invention uses Pro329Gly (antibody Fc segment mutated to glycine at position 329 according to EU numbering, abbreviated as P329G) mutant antibody as a safety switch in the CAR treatment of the present invention. In the absence of the P329G mutant antibody, the CAR activity of the present invention is turned off; in the presence of the P329G mutant antibody, the CAR activity of the present invention is turned on; thus, the opening and closing of the CAR molecule activity of the present invention is regulated by the P329G mutant antibody.

[0324] In some embodiments, the present invention provides a drug combination, which includes (i) immune effector cells (for example, T cells, NK cells) expressing the molecular switch regulating type CAR polypeptides of the present invention;And (ii) P329G mutant antibodies specifically binding BCMA molecules.For example, the immune effector cells are T cells expressing the molecular switch regulating type CAR polypeptides of the present invention prepared from autologous T cells or allogeneic T cells, for example, the immune effector cells are T cells expressing the molecular switch regulating type CAR polypeptides of the present invention prepared from the T cells separated from human PBMC.In some embodiments, the P329G mutant antibody is ADI-38497 PG Ab.

[0325] In some embodiments, the present invention provides a pharmaceutical combination comprising (i) a nucleic acid molecule encoding a molecular switch-regulated CAR polypeptide of the present invention or a vector comprising the nucleic acid component; and (ii) a P329G mutant antibody that specifically binds to a BCMA molecule.

[0326] In some embodiments, the pharmaceutical combination of the present invention optionally further comprises a pharmaceutically acceptable excipient for a suitable formulation. For example, (ii) in the pharmaceutical combination can be formulated according to conventional methods (e.g., Remington's Pharmaceutical Science, latest edition, Mark Publishing Company, Easton, USA).

[0327] In some embodiments, the drug combination of the present invention is used to treat a disease associated with BCMA, such as a cancer that expresses or overexpresses BCMA, such as multiple myeloma, wherein the multiple myeloma is refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma (RRMM).

[0328] VI. Uses of the pharmaceutical combination of the present invention and methods of treatment using the pharmaceutical combination of the present invention

[0329] The present invention provides the aforementioned pharmaceutical combination of the present invention for treating a BCMA-related disease in a subject, such as a cancer that expresses or overexpresses BCMA, such as relapsed / refractory multiple myeloma (RRMM).

[0330] In one embodiment, the pharmaceutical combination of the present invention is used to treat a cancer that expresses or overexpresses BCMA in a subject and is capable of reducing the severity of at least one symptom or indication of the cancer or inhibiting the growth of cancer cells, wherein the cancer is multiple myeloma, such as refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma.

[0331] The present invention provides a method for treating a BCMA-associated disease (e.g., a cancer that expresses or overexpresses BCMA, such as multiple myeloma, for example, refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma) in a subject, comprising administering to an individual in need thereof a therapeutically effective amount of a pharmaceutical combination of the present invention.

[0332] The present invention provides use of the aforementioned drug combination of the present invention in the preparation of a medicament for treating a BCMA-related disease (e.g., a cancer that expresses or overexpresses BCMA, such as multiple myeloma, for example, refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma).

[0333] The pharmaceutical combination of the present invention can also be administered to individuals whose cancer has been treated with at least three prior therapies but has subsequently relapsed or metastasized, for example, the cancer is multiple myeloma, for example, refractory multiple myeloma or relapsed multiple myeloma, such as relapsed / refractory multiple myeloma (RRMM). In some embodiments, the prior therapies include treatment with a proteasome inhibitor and an immunomodulator.

[0334] In some embodiments, the multiple myeloma is refractory multiple myeloma. In some embodiments, wherein the multiple myeloma is relapsed multiple myeloma. In some embodiments, the multiple myeloma is refractory and relapsed multiple myeloma relapsed / refractory multiple myeloma (RRMM). In some embodiments, the subject has received at least three prior therapies for the treatment of multiple myeloma. In some embodiments, the prior therapies include proteasome inhibitors and immunomodulators.

[0335] In some embodiments, the pharmaceutical combination of the present invention (i) expresses the immune effector cells (e.g., T cells, NK cells) of the molecular switch regulating CAR polypeptide of the present invention and (ii) specifically binds to the P329G mutant antibody of the BCMA molecule for parenteral, transdermal, intracavitary, intraarterial, intravenous, intrathecal administration, or directly injected into a tissue or tumor. In some embodiments, the pharmaceutical combination of the present invention (ii) specifically binds to the P329G mutant antibody of the BCMA molecule before (i) expressing the immune effector cells (e.g., T cells, NK cells) of the molecular switch regulating CAR polypeptide of the present invention.

[0336] In some embodiments, (i) the immune effector cells expressing the molecular switch-regulated CAR polypeptide of the present invention in the pharmaceutical combination of the present invention are T cells expressing the CAR polypeptide of the present invention prepared from autologous T cells or allogeneic T cells; (ii) the P329G mutant antibody that specifically binds to the BCMA molecule in the pharmaceutical combination of the present invention is any antibody that specifically binds to the BCMA molecule and comprises a P329G mutation. Preferably, the P329G mutant antibody is ADI-38497 PG Ab.

[0337] In some embodiments, administration of the drug combination of the present invention to an individual suffering from cancer results in the complete disappearance of the tumor. In some embodiments, administration of the drug combination of the present invention to an individual suffering from cancer results in a reduction of tumor cells or tumor size by at least 85% or more. The reduction of the tumor can be measured by any method known in the art, such as X-ray, positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), cytology, histology, or molecular genetic analysis.

[0338] In some embodiments, the drug combination of the present invention can reduce the "on-target / off tumor" toxicity of CAR-T cells.

[0339] VII. Therapy of the Invention

[0340] In some specific embodiments, the present invention relates to a method of treating multiple myeloma in an individual, comprising administering to the individual a drug combination comprising

[0341] (i) The first component, for example, is a T cell expressing a molecular switch-regulated CAR polypeptide, i.e., a CAR-T cell.

[0342] (ii) a second component, e.g., an antibody or antigen-binding fragment that specifically binds to a BCMA molecule comprising a P329G mutation, wherein the P329G mutant antibody comprises a mutant Fc domain in which the amino acid at position P329 according to EU numbering is mutated to glycine (G).

[0343] In some embodiments, the method comprises administering the first component at a dose of approximately 0.5×10 6 cells / kg body weight - approximately 5×10 6 cells / kg body weight, for example, approximately 0.75×10 6 cells / kg body weight, 1×10 6 cells / kg body weight, 1.5×10 6 cells / kg body weight, 2×10 6 cells / kg body weight, 2.5×10 6 cells / kg body weight, 3×10 6 cells / kg body weight, 3.5×10 6 cells / kg body weight, 4×10 6 cells / kg body weight, 4.5×10 6 cells / kg body weight, 5×10 6 In some embodiments, the administration is a single administration or multiple administrations, preferably a single administration. In some embodiments, the administration is intravenous administration.

[0344] In some embodiments, the method comprises administering the second component in a dosage unit of about 0.1-3 mg / kg, preferably about 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg. In some embodiments, the administration is parenteral, more preferably intravenous.

[0345] In some embodiments, the first component and the second component are administered in the following regimen:

[0346] The second component is administered on the first day, and the first component is administered at an interval of about 1-5 hours (e.g., an interval of about 1, 2, 3, 4 or 5); or the second component is administered on the first day and the first component is administered on the second day, with an interval of about 24 hours;

[0347] Taking the first day as the starting date, administer the second component every 1 week (QW), 2 weeks (Q2W), or every 3 weeks (Q3W) in the first cycle;

[0348] Cycle 2 to Cycle n: Administer the second component every three weeks (Q3W) in each cycle.

[0349] In some embodiments, each dosing cycle is 21 days or 28 days.

[0350] In some embodiments, the drug is administered for at least 2-3 cycles. In some embodiments, the drug is administered for at least 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 cycles or more.

[0351] In some embodiments, a lymphodepletion (LD) regimen is administered to the individual. In some embodiments, a lymphodepletion (LD) regimen is administered to the individual prior to administration of the second component. In some embodiments, the lymphodepletion regimen is administered prior to administration of the second component, for example, 1, 2, 3, 4, 5, or 6 days prior to administration. In some embodiments, the duration of LD is about 1 to 5 days, for example, about 3 days. In some embodiments, the time window between the end of LD and the start of administration of the second component, for example, a BCMA antibody, is 2 days, 3 days, or 4 days. In some embodiments, LD is initiated about 3 to 5 days prior to administration of a dose of the second component, for example, a BCMA antibody.

[0352] In some embodiments, LD is initiated about 3, 4, or 5 days prior to administering a dose of the second component, e.g., an anti-BCMA antibody. In some embodiments, a dose of the second component, e.g., an anti-BCMA antibody, is administered about 1, 2, or 3 days after the end of LD.

[0353] In some embodiments, LD comprises fudarapine and cyclophosphamide.

[0354] In some embodiments, the first component, such as CAR-T cells, is prepared within about 20-40 days prior to administering the second component of the present invention. In some embodiments, the first component, such as CAR-T cells, is prepared within about 25-35 days. In some embodiments, the first component comprises T cells. In some embodiments, the T cells are autologous T cells, such as T cells obtained from blood components collected from the subject.

[0355] In some embodiments, the present invention relates to a pharmaceutical combination for use in the methods of treatment of the present invention.

[0356] In some embodiments, after administration of the therapy of the present invention, the probability of the subject developing CRS or ICANS is low, such as less than 50%, such as lower than that of existing BCMA-CAR-T products.

[0357] In some embodiments, the therapies of the present invention have a good safety and / or tolerability profile.

[0358] In some embodiments, the second component (e.g., an anti-BCMA antibody) is capable of modulating the activity of the first component, particularly the cellular activity of CAR-T cells.

[0359] In some embodiments, the therapy of the present invention can partially relieve the disease in the subject. Clinical studies have shown that a total of 11 patients were enrolled, of whom 5 patients achieved PR or above.

[0360] VIII. Kit of the Present Invention

[0361] The present invention provides a kit comprising the pharmaceutical combination of the present invention, preferably in the form of a pharmaceutical dosage unit, whereby the dosage unit can be provided according to a dosing regimen or a drug administration interval.

[0362] In one embodiment, the kit of parts of the present invention comprises in the same package:

[0363] (i) an immune effector cell (e.g., T cell, NK cell) expressing a molecular switch-regulated CAR polypeptide of the present invention, a nucleic acid molecule encoding a molecular switch-regulated CAR polypeptide of the present invention, a vector comprising the nucleic acid, and any combination thereof;

[0364] (ii) P329G mutant antibody that specifically binds to BCMA molecules.

[0365] The various embodiments / technical solutions described in the present invention and the features in each embodiment / technical solution should be understood to be able to be combined with each other arbitrarily, and the various solutions obtained by these combinations are included in the scope of the present invention, just as the solutions obtained by these combinations are specifically and one by one listed in this document, unless the context clearly shows otherwise.

[0366] The following examples are described to assist in understanding the present invention, but are not intended to, and should not be interpreted in any way as, limiting the scope of protection of the present invention. Example

[0367] Example 1. CAR gene synthesis, construction of viral expression vector, preparation of P329G CAR-T cells, and detection of CAR expression

[0368] (1-1) CAR gene synthesis and construction of viral expression vector

[0369] A P329G CAR molecule (SEQ ID NO: 1), also known as HuR968B CAR, was constructed and is composed of a signal peptide (SP) as shown in SEQ ID NO: 11, a specific single-chain antibody fragment recognizing the P329G antibody (VH-linker-VL, having the VH shown in SEQ ID NO: 12, the linker sequence shown in SEQ ID NO: 33, and the VL shown in SEQ ID NO: 13), a G4S hinge region as shown in SEQ ID NO: 14, a CD8 transmembrane domain (CD8TM) as shown in SEQ ID NO: 15, a 41BB costimulatory domain (41BB-CSD) as shown in SEQ ID NO: 16, and a CD3ζ molecule intracellular activation domain (CD3ζSSD) as shown in SEQ ID NO: 17.

[0370] In addition, a Blue21 CAR (SEQ ID NO: 8) directly targeting BCMA was constructed and used as a control. From the N-terminus to the C-terminus, the Blue21 CAR contains the signal peptide shown in SEQ ID NO: 11, an anti-BCMA single-chain antibody (from the 11D53 clone), the hinge region of the CD8α molecule shown in SEQ ID NO: 18, and the CD8 transmembrane domain shown in SEQ ID NO: 15, the 4-1BB costimulatory domain shown in SEQ ID NO: 16, and the CD3ζ chain intracellular activation domain shown in SEQ ID NO: 17.

[0371] The above-mentioned DNA fragments encoding the CAR polypeptide were respectively inserted into the downstream of the EF1α promoter of the pRK lentiviral expression vector (modified by replacing the promoter and resistance gene of the pRRLSIN.cPPT.PGK-GFP.WPRE vector (Addgene, 12252, purchased from Biowind)), replacing the EGFR sequence in the vector, and obtaining the CAR expression plasmids pRK-HuR968B and pRK-Blue21.

[0372] (1-2) Preparation of Lentivirus Concentrate

[0373] The CAR expression plasmid prepared in Example 1-1 was transfected into Lenti-X-293T cells (Takara) at a mass ratio of 3:3:2:2 using the PEI transfection method with the structural plasmid pMDLg / pRRE (Addgene, 12251, purchased from Biowind), the regulatory plasmid pRSV-rev (Addgene, 12253, purchased from Biowind) and the envelope plasmid pMD2G (Addgene, 12259, purchased from Biowind) at a mass ratio of 3:3:2:2. After 16 hours of transfection, the medium was replaced with fresh DEME medium containing 2% fetal bovine serum (FBS). After further culture for 48 hours, the cell supernatant was collected and centrifuged to remove cell debris. PEG8000 was added and incubated at 4°C for 16-64 hours for lentivirus concentration. After centrifugation again, the supernatant was removed and the lentivirus precipitate was resuspended in T cell culture medium to obtain a lentivirus concentrate, which was then aliquoted and frozen at -80°C.

[0374] (1-3) P329G CAR-T cell preparation and CAR expression detection:

[0375] Recombinant human interleukin-2 for injection (National Medical Products Administration No. S20040020) was added to TexMACS GMP Medium (Miltenyi Biotec, 170-076-309) to prepare a T cell culture medium with an IL-2 concentration of 200 IU / ml.

[0376] PBMC cells from multiple donors were obtained from ORiCELLS. The detailed information is shown in Table 1 below:

[0377] Table 1. Related information on the source of donor PBMC cells

[0378] On day 0, the resuscitated PBMCs of each donor were sorted using the Pan T Cell Isolation Kit (human) (Miltenyi, 130-096-535) to obtain T cells. The T cells were resuspended to a certain density in T cell culture medium and activated with TransAct (Miltenyi, 130-111-160).

[0379] On the first day, a certain amount of T cells were separated and cultured without adding lentiviral concentrate. These cells were untransduced cells (UNT, un-transduced T cells), and the remaining T cells were added with the lentiviral concentrate obtained from Example 1-2 at an MOI of 1 to 5 (the lentivirus was a lentivirus encoding P329G CAR (SEQ ID NO: 1) or a control traditional CAR (SEQ ID NO: 8)) and the T cells were blown evenly; on the second day, the viral supernatant was removed by centrifugation and the cells were resuspended in fresh T cell culture medium. On the third day, all cells were transferred to G-Rex (WILSONWOLF, Cat. No. 80040S), and an appropriate amount of fresh T cell culture medium was added and placed in a 37°C CO2 incubator for static culture; every 2 to 3 days, the cells were replaced with fresh culture medium or IL-2 was directly added at half the amount of the culture medium, wherein the IL-2 concentration in the cell culture medium was 200 IU / ml. When the number of cells is expanded to about 20-80 times, the demand is met (generally reaching 2-8x10 8 After centrifugation to remove the culture medium, CAR-T cells were harvested. CS10 (Stemcell, 07930) was resuspended and aliquoted, then programmed to cool to -80°C for freezing.

[0380] An appropriate amount of CAR-T cells were taken, washed once with FACS buffer (PBS + 2% FBS), resuspended, and added to FACS buffer containing LIVE / DEAD Fixable Dead Cell Stain. The cells were stained at room temperature for 10-15 minutes, washed twice, and then added with a combination of PerCP-Cy5.5-CD3, BUV805-CD, Biotin-F(ab')2Fragment goat anti-human IgG (Jackson ImmunoResearch, 109-066-006; PG CAR detection) or Biotin-F(ab')2Fragment goat anti-mouse IgG (Jackson ImmunoResearch, 115-066-006; Blue 21 CAR detection) antibodies. The cells were stained at 4°C for 30-45 minutes. After washing twice, APC-Streptavidin was added and the cells were stained at 4°C for 30-45 minutes. The cells were washed twice, resuspended in FACS buffer, and detected by flow cytometry.

[0381] Figure 1A shows the CD3 + cells, CD4 + 、CD8 +The expression of CAR in T cell subsets showed that the positive rate of CAR expression in these transduced T cells was approximately 18% to 29%.

[0382] Example 2. Detection of BCMA-specific P329G mutant antibody binding activity to antigen

[0383] (2-1) Synthesis of BCMA-specific antibodies

[0384] The heavy and light chain variable region sequences of the BCMA parent antibody ADI-34861 (VH and VL sequences, respectively, as shown in SEQ ID NO: 31 and SEQ ID NO: 32) were obtained from International Application No. PCT / CN2019 / 074419 (a patent related to BCMA antibodies). Based on this parent antibody, CDR regions were mutated to generate the heavy and light chain variable region sequences of ADI-38497 (SEQ ID NO: 2 and SEQ ID NO: 3). Compared to the corresponding parent antibody, the mutated antibody showed significantly improved affinity. Specific experimental data are shown in Table 2 below.

[0385] Table 2 Binding affinity of parental and mutant antibodies to BCMA

[0386] The light and heavy chain variable region sequences of the BCMA antibody clone J6M0 of GSK were obtained from patent US9273141B2 and used as a control antibody (GSK IgG).

[0387] The light and heavy chain variable region sequences of GSK IgG and ADI-38497 antibodies were synthesized using whole-gene synthesis and inserted into pcDNA3.4 expression vectors (purchased from Shanghai Bio-Institute) containing either the WT human IgG1 heavy chain constant region (SEQ ID NO:4) or the human IgG1 heavy chain constant region with the P329G point mutation (SEQ ID NO:5) and the kappa light chain constant region (SEQ ID NO:6). The light and heavy chain expression vectors were co-transfected into HEK293 cells using polyethylene glycol (PEI) at a 2:3 molar ratio. After 5-7 days of culture, the culture supernatant was collected. The antibody-containing supernatant was purified by a single step using a Protein A column and then dialyzed against PBS. Concentration was determined by absorbance at 280 nm using a NanoDrop instrument, and sample purity was assessed by SDS-PAGE and SEC-HPLC. GSK WT and GSK PG antibodies, as well as ADI-38497 WT and ADI-38497 PG antibodies, were obtained. Antibodies having the sequences of the heavy chain variable region (SEQ ID NO: 2) and light chain variable region (SEQ ID NO: 3) of the BCMA antibody clone ADI-38497 are also referred to herein as ADI-38497 antibodies, including ADI-38497 PG antibody (comprising a P329G mutation) and ADI-38497 WT antibody.

[0388] (2-2) Antibody affinity testing

[0389] The affinity of ADI-38497 PG antibody to BCMA from different species was determined using Biacore T200. Figure 2A shows a schematic diagram of the method for determining antibody affinity using surface plasmon resonance (SPR).

[0390] The specific method is as follows: Anti-human Fc IgG (Ab97221, Abcam) was coupled to the surface of a CM5 chip (29149603, Cytiva). ADI-38497 PG antibody was then captured on the chip surface. Affinity and kinetic constants were determined by measuring the binding and dissociation between the antibody on the chip surface and the BCMA antigen in the mobile phase. The assay used a 10-fold diluted 10× HBS-EP+ (BR-1006-69, Cytiva) as the assay buffer. Each cycle of the affinity assay consisted of capture of the ADI-38497 PG antibody, binding of one antigen concentration, and chip regeneration. A gradient of antigen dilutions (1.25-40 nM, 2-fold dilutions) was flowed over the chip surface in ascending order at a flow rate of 30 μl / min. The binding time was 180 s, and the appropriate dissociation time (900 s, 600 s, or 60 s) was set. Finally, the chip was regenerated using 10 mM glycine-HCl, pH 1.5 (BR-1003-54, Cytiva).

[0391] The data were analyzed using Biacore T200 analysis software (version 3.1) using a 1:1 binding model.

[0392] Figure 2B shows representative affinity profiles of ADI-38497 PG antibody for recombinant human, cynomolgus macaque, mouse, rat, and rabbit BCMA proteins measured using SPR. The results show that ADI-38497 PG antibody binds to BCMA proteins from all of the species listed above, with the order of binding activity being human BCMA > monkey BCMA > mouse BCMA > rat BCMA > rabbit BCMA.

[0393] Table 3 Binding affinity of ADI-38497 PG antibody to BCMA proteins from different species

[0394] (2-3) Detection of the binding activity of P329G BCMA antibody to BCMA antigens from different species

[0395] First, CHO GS cells expressing BCMA antigens from different species were generated. Specifically, BCMA genes from humans, mice, and cynomolgus macaques were synthesized and cloned into lentiviral vectors. Lentiviruses containing BCMA genes from different species were then packaged and used to infect CHO GS cells. Subsequently, flow cytometry was used to sort these cells to generate CHO GS cell lines expressing BCMA antigens from different species, namely hBCMA-CHO GS, mBCMA-CHO GS, and cynoBCMA-CHO GS cells.

[0396] ADI-38497 PG antibody and GSK-derived BCMA antibody (i.e., GSK PG IgG was used as a benchmark) were then diluted 10-fold in FACS buffer to prepare different concentrations of antibody solutions. These solutions were incubated with 1E5 CHO GS cells expressing BCMA antigens from different species at 4°C for 30 minutes. After washing with FACS buffer, the cells were incubated with Fcγ fragment-specific APC-goat anti-human IgG (Jackson ImmunoResearch, 109-136-098) at 4°C for 30 minutes. Flow cytometry was used to detect cell-bound P329G antibody. The MFI in the APC channel was analyzed, and a plot was drawn with antibody concentration on the X-axis and the MFI in the APC channel on the Y-axis. The EC50 for binding was calculated.

[0397] Figure 2C shows the binding ability of different concentrations of the P329G BCMA antibody to CHO-GS cells stably expressing human, cynomolgus macaque, and mouse BCMA. As shown in Figure 2C, the ADI-38497 PG IgG antibody can bind to BCMA expressed on the cell surface from different species, while the GSK-derived BCMA antibody (Benchmark) has high species specificity for BCMA and does not recognize mouse BCMA, a result consistent with the SPR assay results.

[0398] Table 4 EC50 values ​​of the binding of P329G BCMA antibody to CHO-GS cells expressing BCMA of different species

[0399] (2-4) Detection of the binding activity of P329G BCMA antibody to BCMA antigen on tumor cell surface

[0400] An appropriate amount of tumor cells in the logarithmic growth phase were collected and washed twice with FACS buffer. ADI-38497 PG antibody and GSK PGIgG used as a benchmark were added. For the cells used as staining controls, isotype hIgG1 antibody was added and stained at 4°C for 30 minutes. The cells were washed twice and goat anti-human IgG antibody against APC-F(ab')2 fragment was added and stained at 4°C for 30 minutes. The cells were washed twice and resuspended in FACS buffer for detection by flow cytometry.

[0401] Figure 2D shows the binding activity of different concentrations of P329G BCMA antibody to BCMA-expressing positive multiple myeloma cell lines MM.1s, RPMI8226, U266, H929, L363, and AMO1 (MM.1s was purchased from Nanjing Kebai Biotechnology Co., Ltd., CBP60239; RPMI8226 was purchased from Nanjing Kebai Biotechnology Co., Ltd., CBP60244; U266 was purchased from Wuhan Pronosai Life Science Co., Ltd., CL-0510; H929 was purchased from Nanjing Kebai Biotechnology Co., Ltd., CBP60243; L363 was purchased from Nanjing Kebai Biotechnology Co., Ltd., CBP6024; AMO1 was purchased from Nanjing Kebai Biotechnology Co., Ltd., CBP60242). The ADI-38497 PG antibody was able to bind to BCMA-expressing positive tumor cells in a concentration-dependent manner. Among the BCMA-expressing positive tumor cells, MM.1s cells expressed the highest level of BCMA, RPMI8226, U266, and H929 cells expressed BCMA at intermediate levels, and L363 and AMO1 cells expressed BCMA at low levels.

[0402] Table 5 EC50 values ​​of the binding of P329G BCMA antibody to BCMA-expressing positive tumor cells

[0403] Example 3. Detection of Binding Activity of BCMA-Specific P329G Mutant Antibody to the Extracellular Domain of P329G CAR

[0404] (3-1) Affinity detection of the binding of the P329G mutant antibody to the extracellular domain of the P329G CAR

[0405] The binding affinity of ADI-38497 molecules (P329G mutant antibody or wild-type antibody) to an anti-P329G mutation-specific single-chain antibody-rabbit Fc fusion protein (also referred to as "anti-PG scFv fusion protein" or simply "anti-PG scFv") was determined using Biacore T200. Figure 3A shows a schematic diagram of the surface plasmon resonance (SPR) assay for binding affinity between the anti-P329G mutation-specific single-chain antibody-rabbit Fc fusion protein and the ADI-38497 P329G mutant antibody.

[0406] The specific method is as follows: A synthetic anti-PG scFv fusion protein (SEQ ID NO: 7) was coupled to the surface of a C1 chip (BR100535, Cytiva). Affinity and kinetic constants were determined by measuring the binding and dissociation of the antibody on the chip surface with ADI-38497 molecules in the mobile phase. The assay used a 10-fold diluted 10× HBS-EP+ (BR-1006-69, Cytiva) as the assay buffer. Each cycle of affinity measurement consisted of binding one concentration of antibody and chip regeneration. A serial dilution of ADI-38497 (3.125 nM to 100 nM, 2-fold dilution) was flowed over the chip surface in ascending order at a flow rate of 30 μl / min, with an association time of 180 s and a dissociation time of 300 s. Finally, the chip was regenerated using 10 mM Glycine-HCl, pH 1.5 (BR-1003-54, Cytiva).

[0407] The data were analyzed using Biacore T200 analysis software (version 3.1) using a 1:1 binding model.

[0408] Figure 3B shows representative affinity profiles of ADI-38497 PG antibody and wild-type antibody binding to the anti-PG scFv fusion protein using SPR. The results show that only ADI-38497 PG antibody can specifically bind to the anti-PG scFv, which serves as the extracellular domain of the P329G CAR.

[0409] Table 6 Affinity of P329G BCMA antibody and wild-type antibody to anti-PG scFv determined by SPR

[0410] (3-2) Binding affinity detection of ADI-38497 molecule and anti-PG scFv fusion protein

[0411] The binding affinity of ADI-38497 (P329G mutant antibody or wild-type antibody) to anti-PG scFv fusion protein was determined by Biacore T200. Figure 3C shows a schematic diagram of the method for determining antibody affinity using surface plasmon resonance (SPR).

[0412] The specific method is as follows: Anti-Fab IgG (I5260, Sigma) is coupled to the surface of an HLC chip (HLC30M, Xantec). ADI-38497 molecules are captured on the chip surface. Binding affinity and kinetic constants are determined by measuring the binding and dissociation of the antibody on the chip surface with the anti-PG scFv fusion protein in the mobile phase. The assay uses 10x diluted 10× HBS-EP+ (BR-1006-69, Cytiva) as the assay buffer. Each cycle of affinity assay involves capturing ADI-38497 molecules, binding to a single concentration of anti-PG scFv, and chip regeneration. A gradient of dilutions (1.25 nM to 40 nM, 2-fold dilutions) of anti-PG scFv is flowed over the chip surface in ascending concentrations at a flow rate of 30 μl / min, with an association time of 180 s and a dissociation time of 300 s. Finally, the chip was regenerated using 10 mM glycine-HCl, pH 1.5 (BR-1003-54, Cytiva).

[0413] The data were analyzed using Biacore T200 analysis software (version 3.1) using a 1:1 binding model.

[0414] Figure 3D shows representative affinity profiles of ADI-38497 PG antibody and wild-type antibody binding to the anti-PG scFv, the extracellular domain of the P329G CAR, as determined by SPR. The results show that only the ADI-38497 PG antibody can specifically bind to the P329G CAR.

[0415] Table 7 Affinity of P329G BCMA antibody and wild-type antibody with anti-PG scFv determined by SPR

[0416] (3-3) Detection of the binding activity of P329G BCMA antibody and P329 CAR

[0417] The P329G CAR-T cells prepared in Example 1 were resuspended in RPMI 1640 medium containing 10% FBS and incubated at 37°C for 24 hours. ADI-38497 PG and wild-type ADI-38497 WT antibodies were prepared in FACS buffer to prepare 5-fold serial dilutions of different concentrations. Each solution was incubated with 1E5 CAR-positive cells at 4°C for 30 minutes. After washing with FACS buffer, the cells were incubated with Fcγ fragment-specific APC goat anti-human IgG (Jackson ImmunoResearch, 109-136-098) at 4°C for 30 minutes. Antibody binding to cells was detected by flow cytometry, and the MFI in the APC channel was analyzed. The binding EC50 was calculated by plotting the antibody concentration on the X-axis and the APC channel MFI on the Y-axis.

[0418] Figure 3E shows the binding ability of ADI-38497 WT and ADI-38497 PG antibodies to P329G CAR-T cells. The results showed that only the P329G mutant antibody showed binding to CAR, while the WT antibody did not, which was consistent with the SPR results.

[0419] Table 8 summarizes the EC50 and EC90 values ​​of ADI-38497 PG and WT antibodies binding to P329G CAR-T cells from different donors.

[0420] Table 8 EC50 and EC90 values ​​of BCMA IgG antibody binding to CAR-T cells

[0421] Example 4. Detection of Fc domain function of BCMA-specific P329G mutant antibody

[0422] (4-1) ADCC effector function assay of ADI-38497 PG antibody

[0423] PBMCs (peripheral blood mononuclear cells) from donor 3 were resuspended in RPMI 1640 medium and stabilized at 37°C for 1-2 hours. PBMCs and target cells were mixed at a 25:1 effector-target ratio and incubated with different concentrations of BCMA antibodies. Incubation continued at 37°C for 4 and 24 hours. Antibody-mediated cytotoxicity of PBMCs against target cells was detected using an LDH assay kit (Promega, G1780). The antibody concentration was plotted on the X-axis and the cell lysis percentage on the Y-axis for analysis. Cells were collected and washed twice with FACS buffer. Antibodies to CD3, CD56, CD16, and CD107a were added, with CD107a added in advance, and incubated with the cells at 37°C for 1 hour. The cell-antibody mixture was stained at 4°C for 30 minutes, washed twice, resuspended in FACS buffer, and analyzed using flow cytometry.

[0424] Figure 4A shows the ability of ADI-38497 WT antibody and ADI-38497 PG antibody to mediate ADCC killing. The results showed that when different incubation times (4 hours, 24 hours) and different detection indicators (cytotoxicity on target cells, effects on CD3, CD56, CD16 and CD107a expression) were tested, only the WT antibody mediated ADCC cytotoxic killing effect on BCMA-expressing positive H929 tumor cells, while the P329G mutant antibody lacked the ability to induce ADCC effect.

[0425] (4-2) ADCP effector function assay of ADI-38497 PG antibody

[0426] ADCP reporter cell lines (Promega, G9871) and H929 cells in the logarithmic growth phase were taken, and the ADCP reporter cells and H929 target cells were mixed at effector-target ratios of 2:1 and 5:1, and then mixed with different concentrations of BCMA antibodies. The cells were cultured at 37°C for 20 hours, and the antibody-mediated target cell-dependent reporter cell activation effect was detected using a luciferase assay kit (Promega, E2620). The antibody concentration was used as the X-axis and the fluorescence reading change was used as the Y-axis for plotting and analysis.

[0427] Figure 4B shows the ability of ADI-38497 WT and ADI-38497 PG antibodies to mediate ADCP cytotoxicity. The results showed that when different effector-target ratios (2:1 or 5:1) were tested, only ADI-38497 WT mediated ADCP cytotoxicity against BCMA-expressing H929 tumor cells, while the P329G mutant antibody lacked the ability to induce ADCP cytotoxicity against BCMA-expressing H929 tumor cells.

[0428] (4-3) Functional testing of whether ADI-38497 PG antibody alone mediates target cell lysis

[0429] Logarithmically growing H929 and L363 cells were plated in appropriate numbers in well plates. A portion of these cells were treated with mitomycin C as target cells and used as a negative control. Subsequently, various concentrations of ADI-38497 PG antibody were added and the cells were cultured at 37°C for 48, 72, and 120 hours. The proportion of viable cells was determined using CellTiter-Glo (Promega, G9242). The fluorescence readings were plotted and analyzed using the incubation time as the X-axis and the incubation time as the Y-axis.

[0430] Figure 4C shows the ability of ADI-38497 PG antibody to mediate target cell lysis. The results show that when different incubation times (48 hours, 72 hours, and 120 hours) and different ADI-38497 PG antibody concentrations (5 μg / ml, 50 μg / ml) were tested, ADI-38497 PG antibody alone lacked the ability to induce target cell lysis.

[0431] Example 5. In vitro functional study of P329G CAR-T

[0432] (5-1) CAR-T cell activation detection

[0433] The CAR-T cells prepared from donor 5 in Example 1 were revived and cultured stably overnight at 37°C. H929 or L363 tumor target cells and CAR-T cells were mixed at an E:T ratio of 2:1, and 5-fold or 10-fold serial dilutions of different concentrations of ADI-38497 PG antibody solution were added to a total volume of 200 μL. The cells were cultured at 37°C for about 24 hours and then centrifuged to collect the cells. The cells were washed twice with FACS buffer, resuspended, and added with FACS buffer containing LIVE / DEAD Fixable Dead Cell Stain and Biotin-F(ab')2Fragment goat anti-human IgG (Jackson ImmunoResearch, 109-066-006). The cells were stained at 4°C for 30 minutes, washed twice, and CD4, CD8, CD25, CD69, and APC-Streptavidin antibody combinations were added. The cell-antibody mixture was stained at 4°C for 30 minutes, washed twice, resuspended in FACS buffer, and detected by flow cytometry.

[0434] Figure 5A shows that only the ADI-38497 PG antibody containing the P329G mutation can specifically mediate CAR against H929 cells. +-T activation, upregulating the expression levels of CD25 and CD69, and + CAR + and CD8 + CAR + Cells were activated in an indifferent manner and in a concentration-dependent manner according to the ADI-38497 PG antibody.

[0435] Figure 5B shows the activation effect of L363 target cells on HuR968B CAR-T cells induced by different BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, GSK PG IgG). As shown in Figure 5B, BCMA antibodies containing the P329G mutation (ADI-38497 PG antibody, GSK PG IgG) can specifically mediate the activation of CAR+T cells and significantly upregulate the expression levels of CD25 and CD69. The expression of CD25 and CD69 in the CAR-negative cell population was also slightly upregulated, indicating a lower level of activation, but the degree of activation was not significant and could be ignored.

[0436] Therefore, whether H929 cells with high BCMA expression (Figure 5A) or L363 cells with low BCMA expression (Figure 5B) were used as target cells, only BCMA antibodies containing the P329G mutation (ADI-38497 PG antibody, GSK PG IgG) could specifically mediate CAR + -T activation significantly upregulated the expression levels of CD25 and CD69, and was dependent on the concentration gradient of BCMA antibodies with the P329G mutation.

[0437] (5-2) CAR-T cell proliferation assay

[0438] The UNT cells and CAR-T cells prepared from donor 4 in Example 1 were revived and cultured stably at 37°C overnight. ADI-38497 WT antibody or ADI-38497 PG antibody was diluted with PBS, added to a 96-well plate and incubated overnight at 4°C to coat the plate. The CAR-T cells recovered after overnight culture were added to the 96-well plate coated with the antibody. As a positive control, CD3 / CD28-coupled magnetic beads (bead: cell ratio 3:1) were directly added to the CAR-T cells; they were incubated at 37°C for 72 hours and 120 hours, respectively. Luminescent Cell Viability Assay (Promega, G7572) was used to detect the luminescence value of cells.

[0439] Figure 5C shows the proliferation of HuR968B CAR-T cells after stimulation with coated ADI-38497 WT or ADI-38497 PG antibodies. HuR968B CAR-T cells proliferated upon stimulation with coated ADI-38497 P329G antibody. Compared to stimulation with ADI-38497 WT antibody, ADI-38497 PG antibody increased HuR968B CAR-T cell proliferation by approximately 7-fold or 43.5-fold after 3 or 5 days of stimulation, respectively. In contrast, stimulation with ADI-38497 PG antibody did not significantly increase the proliferation of UNT cells compared to stimulation with ADI-38497 WT antibody. Both HuR968B CAR-T cells and UNT cells proliferated significantly upon stimulation with CD3 / CD28 antibody-coupled magnetic beads.

[0440] (5-3) Cytokine Detection

[0441] The CAR-T cells prepared in Example 1 were revived and cultured stably at 37°C overnight. Tumor target cells and CAR-T cells were mixed at an E:T ratio of 2:1, and 5-fold or 10-fold gradient dilutions of different concentrations of BCMA antibody (ADI-38497 PG antibody, ADI-38497 WT antibody, or GSK PG IgG as a benchmark) solution were added to a total volume of 200 μL. The cells were cultured at 37°C for about 24 hours and then centrifuged to collect the supernatant. BD Biosciences TM Cytokine detection was performed using the Cytometric Bead Array (CBA) Human Th1 / Th2 Cytokine Kit II (BD, 551809). After mixing equal volumes of Capture Beads in the kit, plate the beads at 25 μL / well. Add an equal volume of supernatant, supernatant dilution, or standard. After mixing, add 25 μL of Human Th1 / Th2 PE Detection Reagent and incubate at room temperature in the dark for 3 hours. Wash twice with wash buffer and resuspend. Analyze using flow cytometry, and calculate cytokine concentrations based on the MFI value in the PE channel.

[0442] Figure 5D shows the release of effector cytokines secreted by CAR-T cells after the addition of different concentrations of BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or GSK PG IgG as a positive control) when HuR968B CAR-T cells from donor 4 in Example 1 were co-cultured with H929 cells and RPMI8226 cells.

[0443] Figure 5E shows the release of effector cytokines secreted by CAR-T cells after the addition of different concentrations of BCMA antibodies (ADI-38497 PG antibody, ADI-38497 WT antibody, or Benchmark GSK PG IgG) after HuR968B CAR-T cells from donor 5 (purchased from ORiCELLS, Cat NO.: FPB004F-C, Lot NO.: PCH20210100004, Donor ID: Z0086) were co-cultured with different tumor cells.

[0444] As can be seen from Figures 5D and 5E, when WT BCMA antibody (ADI-38497 WT antibody) was added, HuR968B CAR-T cells were not activated and did not secrete effector cytokines such as IL-2, IFN-γ, and TNFα. Only when BCMA antibody containing the P329G mutation (ADI-38497 PG antibody or GSK PG IgG as a positive control) was added, HuR968B CAR-T cells were activated and secreted effector cytokines. Moreover, according to the cytokine secretion results under different target cell conditions, there was no obvious correlation between the level of cytokine secretion by effector cells and the BCMA expression level of target cells.

[0445] (5-4) Killing efficiency test

[0446] The CAR-T cells prepared in Example 1 were revived and cultured stably at 37 ° C overnight. The tumor target cells and CAR-T cells were mixed at an E: T ratio of 2: 1, and 10-fold gradient dilutions of different concentrations of BCMA antibody (ADI-38497 PG antibody, ADI-38497 WT antibody, or Benchmark GSK PG IgG) solution were added to a total volume of 200 μL, cultured at 37 ° C for about 24 hours, and then centrifuged. The cell supernatant was transferred to a 96-well white bottom ELISA plate. The LDH value in the supernatant was measured using CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, G1780) and an ELISA reader (Molecular Devices, SpectraMax i3x) to calculate the killing efficiency.

[0447] Figure 5F shows the effect of different BCMA antibodies (ADI-38497 PG antibody, ADI-38497WT antibody, or Benchmark GSK PG IgG) on HuR968B CAR-T cells against tumor cells with different BCMA expression levels (H929 ++ Cells, RPMI8226 +++ cells, AMO1 +cells and L363 + In the case of adding WT BCMA antibody, HuR968B cells are not activated and do not produce a killing effect on tumor cells. Only when adding BCMA antibodies containing P329G mutations, P329G CAR-T cells are activated, thereby killing target cells, and are antibody concentration-dependent, which is consistent with the above-mentioned CAR-T cell activation and effector cytokine results in this embodiment. In addition, in the case of H929 and RPMI8226 cells with high BCMA expression as target cells, the killing effect of P329G BCMA antibody-mediated HuR968B CAR-T cells is higher than that of AMO1 and L363 target cells with low BCMA expression.

[0448] Figure 5G shows that neither the P329G BCMA antibody nor the WT BCMA antibody mediates the killing effect of CAR-T on BCMA-negative target cells (such as BCMA-KO-H929 cells). WT BCMA antibody also cannot mediate the killing effect on H929 cells (H929) expressing BCMA. Only the P329G BCMA antibody can induce CAR-T to produce a killing effect on tumor cells.

[0449] Table 9 EC50 values ​​of the killing effect of HuR968B CAR-T cells mediated by P329G BCMA antibody on H929 target cells

[0450] Example 6: Effect of Free BCMA Protein on PG CAR-T Function

[0451] (6-1) Killing efficiency test

[0452] The CAR-T cells prepared by donor 6 in Example 1 were revived and cultured stably at 37°C overnight. The tumor target cells and CAR-T cells were mixed at an E:T ratio of 2:1, and a certain concentration of PG BCMA antibody was added. For traditional Blue21 CAR-T, BCMA antibody was not required. 10-fold gradient dilutions of different concentrations of BCMA protein solution were added as free BCMA protein to a total volume of 200 μL, cultured at 37°C for about 24 hours, and then centrifuged. The cell supernatant was transferred to a 96-well white bottom enzyme plate. The LDH value in the supernatant was measured using CytoTox 96 Non-Radioactive Cytotoxicity Assay (Promega, G1780) and an enzyme reader (Molecular Devices, SpectraMax i3x) to calculate the killing efficiency.

[0453] Figure 6 shows the effect of different concentrations of free BCMA protein on the killing effect of HuR968B CAR-T and Blue21 CAR-T cells. When different concentrations of free BCMA protein are added, once the traditional CAR T cell binds to the free BCMA protein, its function will be blocked (due to the high affinity of the traditional CAR molecule for BCMA), while when the PG BCMA antibody binds to the soluble BCMA, the PG CAR-T can still exert a normal killing effect. Therefore, the advantage of PG CAR-T cells is that their function is less affected by soluble ligands (such as soluble BCMA).

[0454] Example 7: In vivo pharmacokinetic study of ADI-38497 PG antibody

[0455] (7-1) Antibody injection and sampling

[0456] Female BALB / c mice (aged 4-6 weeks, weighing 15-17 g) were divided into three groups: ADI-38497 PG antibody (1 mg / kg), ADI-38497 PG antibody (10 mg / kg), and ADI-38497 PG antibody (200 mg / kg), with nine mice per group. The antibody was diluted in 1× PBS to 0.1 mg / mL, 1 mg / mL, and 20 mg / mL, respectively. Each mouse received a single intravenous injection, giving a single dose of 1 mg / kg, 10 mg / mL, and 200 mg / mL. Blood samples (100 μL) were collected from the retroorbital venous plexus of the mice at 5 minutes, 30 minutes, 2 hours, 6 hours, 24 hours, 48 ​​hours, 96 hours, 168 hours, 336 hours, and 504 hours after antibody administration. The samples were centrifuged at 3000 g, and the supernatant was collected for plasma concentration determination.

[0457] (7-2) ADI-38497 PG Antibody Detection

[0458] Coat a 96-well ELISA plate one day in advance. Dilute BCMA antigen to 1 μg / mL using coating solution (dissolve one packet of carbonate (Thermo, 28382) powder in 400 mL of ultrapure water, dilute to 500 mL, and mix thoroughly). Add 100 μL per well of BCMA antigen. Seal the plate with a sealing film and incubate at room temperature overnight. Discard the coating solution, pat dry on absorbent paper, then add 300 μL of wash solution to each well, vortex to mix for 10 seconds, pat dry, and repeat the wash three times. Add 200 μL of blocking solution to each well using a pipette, seal the plate with a sealing film, and incubate at room temperature for 2 hours. Wash the plate once. Add 100 μL of the diluted standard curve (prepared by serial dilutions of BCMA antibody with known concentrations, for example, using ADI-38497 PG antibody with known concentrations), quality control samples, and test samples to each well and incubate at room temperature for 2 hours. Discard the pre-coating solution and pat dry on absorbent paper. Then, add 300 μL of wash buffer to each well and vortex to mix for 10 seconds. After patting dry, repeat the wash three times. Repeat once. Dilute goat anti-human IgG-Fc-HRP antibody (BETHYL) 1:100,000 and add 100 μL to each well. Incubate at room temperature in the dark for 1 hour. Wash the plate once. Add 100 μL of TMB substrate to a 96-well microtiter plate and develop at room temperature in the dark for 5 minutes. Add 50 μL of ELISA stop buffer to each well and vortex for 10 seconds. Read OD450 nm and OD620 nm values ​​within 30 minutes.

[0459] Figures 7A and 7B show the results of pharmacokinetic experiments of ADI-38497 PG antibody (hereinafter referred to as PG Ab in the mouse in vivo experiments) in mice. After intravenous injection of 1 mg / kg, 10 mg / kg, and 200 mg / kg of ADI-38497 PG antibody in mice, the exposure of ADI-38497 PG antibody in serum (Cmax and AUClast) showed a dose-dependent effect, and there were no significant differences in other pharmacokinetic parameters. As shown in Table 10, ADI-38497 PG antibody 1 mg / kg: AUC0-inf, Cmax, CL, T1 / 2 were 2480 μg×h / mL, 30 μg / ml, 0.40 ml / kg / h, and 145 h, respectively; ADI-38497 PG antibody 10 mg / kg: AUC0-inf, Cmax, CL, T1 / 2 were 24720 μg×h / mL, 187 μg / ml, 0.32 ml / kg / h, and 219 h, respectively; PG antibody 200 mg / kg: AUC0-inf, Cmax, CL, T1 / 2 were 397734 μg×h / mL, 3895 ug / ml, 0.43 ml / kg / h, 197 h, respectively. The half-life of ADI-38497 PG antibody 1 mg / kg was slightly shorter than that of ADI-38497 PG antibody 10 mg / kg and 200 mg / kg.

[0460] Table 10 ADI-38497 PG antibody pharmacokinetic experimental results

[0461] Example 8. Effect of PG CAR-T cells combined with different doses of PG antibodies against BCMA-highly expressed tumors in vivo

[0462] (8-1) Mouse tumor inoculation and treatment

[0463] Resuspend H929 cells in 1× PBS to prepare a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right side of their backs and subcutaneously injected with H929 cell suspension at a volume of 0.2 mL per mouse, i.e., an inoculum size of 1×10 6 cells / mouse. 7 days after tumor cell inoculation, the tumor volume of mice ranged from 50.82 to 104.36 mm 3 The mice were divided into 7 groups, namely PBS vehicle group, PG Ab group, PG CAR-T group only, traditional CAR-T group, PG Ab + PG CAR-T, 3mg / kg antibody group, PG Ab + PG CAR-T, 1mg / kg antibody group and PG Ab + PG CAR-T, 0.3mg / kg antibody group, with 7 mice in each group. The antibodies were prepared at concentrations of 0.3mg / mL, 0.1mg / mL and 0.03mg / mL respectively. After grouping, the antibodies were administered on the 7th day. The volume of each mouse was 10mL / kg. The frequency of administration was once a week and the administration method was intraperitoneal injection. The CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR + The cells were 25×10 6 On the 7th day, 0.2 mL of cell suspension was injected into the tail vein of each animal, and CAR was then injected. + Cells 5×10 6 The body weight, maximum longitudinal axis (L) and maximum width axis (W) of the tumor tissue were monitored twice a week.

[0464] Figure 8A shows the therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells that highly express BCMA. The results showed that in the BCMA-high-expressing tumor model, the administration of PG CAR-T cells alone did not produce a significant anti-tumor effect, while the administration of PG antibody alone produced a certain anti-tumor effect. Only mice treated with both PG CAR-T cells and PG antibody produced a significant anti-tumor effect, and the effect was dose-dependent. Treatment with PG CAR-T cells combined with 0.3 mg / kg antibody, 1 mg / kg antibody, and 3 mg / kg antibody resulted in tumor growth inhibition rates (TGIs) of 92%, 88%, and 101%, respectively, while the anti-tumor efficacy TGIs in mice treated with only PG CAR-T cells or only PG antibody were 25% and 53%, respectively. In addition, the anti-tumor effect of PG CAR-T cells combined with 3 mg / kg PG antibody was comparable to the anti-tumor effect of conventional Blue21 CAR-T cells at the same dose, with TGIs of 101% and 102%, respectively.

[0465] Figure 8B shows the weight changes of mice in this experiment. The results showed that the weight of mice treated with PG CAR-T cells combined with PG antibodies remained stable after treatment, with average weight increases of 5.2%, 3.0%, and 7.6% after treatment with 0.3 mg / kg, 1 mg / kg, and 3 mg / kg of PG antibodies, respectively. These results demonstrate that PG CAR-T cells combined with PG antibodies produced a significant anti-tumor effect without significant toxic side effects.

[0466] (8-2) CAR-T cell detection in mice:

[0467] Take 30 μL of the mouse blood sample from Example 8-1 and add it to a 96-well V-well plate, marked as the sample test well; take 10 μL of the mouse blood sample and add it to a 96-well V-well plate, marked as the control well. Add 100 μL of LIVE / DEAD Fixable Dead Cell Stain and TruStain FcX to all wells. TM(anti-mouse CD16 / 32) (Biolegend) FACS buffer, gently mix, incubate at 4°C in the dark for 15 minutes; then add Biotin-F(ab')2 fragment Fragment goat anti-human IgG antibody to the sample detection well, incubate at 4°C in the dark for 30 minutes; then add 100 μL FACS buffer to each sample detection well, centrifuge at 400g, and discard the supernatant; add 100 μL FACS buffer containing APC-Cy7 anti-human CD45 (Biolegend), PerCP-Cy5.5-CD3 (BD ​​Biosciences) and APC-streptavidin (Biolegend) to each well, gently mix, incubate at 4°C in the dark for 30 minutes; then add 200 μL / well FACS buffer to all wells, centrifuge at 400g, and discard the supernatant; add 250 μL / well 1× RBC Lysis / Fixation solution (Biolegend), mix well, incubate at room temperature in the dark for 20 minutes; centrifuge at 400g, discard the supernatant; resuspend the cells in 100 μL FACS buffer, add 10 μL 123count eBeads to each well, and detect using flow cytometer.

[0468] Figure 8C shows the expansion of PG CAR-T cells in mice in the experiment of Example 8-1. The results showed that the expansion of PG CAR-T cells in vivo depended on PG antibodies, showing a certain antibody dose dependence, and mice in the higher dose group had a higher level of PG CAR-T cell expansion. When only PG CAR-T cells were administered, they began to expand one week after being reinfused into the mice, expanded to 466 cells / 100 μL peripheral blood after 2 weeks, and expanded to a higher level (3644 cells / 100 μL peripheral blood) after 3 weeks. After 4 weeks, the expansion still remained at a high level (3214 cells / 100 μL peripheral blood); when PG CAR-T cells were used in combination with different doses of PG antibodies 0.3 mg / kg, 1 mg / kg, and 3 mg / kg, PG CAR-T cells expanded after 2 weeks. Peak in vivo expansion levels of CAR-T cells reached 11,428 cells / 100 μL of peripheral blood, 19,299 cells / 100 μL of peripheral blood, and 35,368 cells / 100 μL of peripheral blood, respectively. Four weeks later, these levels remained high, reaching 15,486 cells / 100 μL of peripheral blood, 25,073 cells / 100 μL of peripheral blood, and 27,666 cells / 100 μL of peripheral blood, respectively. These levels were significantly higher than those observed in the non-antibody co-administered group over the same period. Furthermore, conventional Blue21 CAR-T cells, used as a positive control, displayed similar expansion kinetics, beginning to expand within one week of infusion into mice, reaching a peak of 174,769 cells / 100 μL of peripheral blood two weeks later, and remaining at very high levels (131,963 cells / 100 μL of peripheral blood) four weeks later.

[0469] Example 9: Effects of PG CAR-T cells combined with different doses of PG antibodies against BCMA-low expressing tumors in vivo

[0470] (9-1) Mouse tumor inoculation and treatment

[0471] Resuspend L363 cells in 1× PBS to prepare a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right side of their backs and injected subcutaneously with L363 cell suspension at a volume of 0.2 mL per mouse, i.e., an inoculum of 1×10 6 cells / mouse. 9 days after tumor cell inoculation, the tumor volume of the mice ranged from 74.14 to 110.29 mm 3 The mice were divided into 7 groups, namely vehicle group, PG Ab group, PG CAR-T group, traditional CAR-T group, PG Ab+PG CAR-T, 3mg / kg antibody group, PG Ab+PG CAR-T, 1mg / kg antibody group and PG Ab+PG CAR-T, 0.3mg / kg antibody group, with 7 mice in each group. The antibodies were prepared at concentrations of 0.3mg / mL, 0.1mg / mL and 0.03mg / mL respectively. After grouping, the antibodies were administered on the 9th day. The volume of each mouse was 10mL / kg. The frequency of administration was once a week and the administration method was intraperitoneal injection. The CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR + The cells were 25×10 6 On the 9th day, 0.2 mL of cell suspension was injected into the tail vein of each animal, and CAR was then injected. + Cells 5×10 6 The body weight, maximum longitudinal axis (L) and maximum width axis (W) of the tumor tissue were monitored twice a week.

[0472] Figure 9A shows the therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human L363 low-expressing BCMA tumor cells. The results showed that in this low-expressing BCMA tumor model, administration of PG CAR-T alone did not produce an anti-tumor effect, while administration of PG antibody alone had a weak anti-tumor effect, with a TGI of 21%. Only mice treated with both PG CAR-T cells and PG antibody produced a significant anti-tumor effect, which was dose-dependent. When PG CAR-T cells were combined with 0.3 mg / kg of PG antibody, PG CAR-T cells induced a significant anti-tumor effect, with a TGI of 87%. When the PG antibody dose was increased to 1 mg / kg and 3 mg / kg in this combination, the maximum anti-tumor effect induced by PG CAR-T cells increased significantly, with TGIs of 103% and 103%, respectively, demonstrating the same anti-tumor effect as traditional Blue21 CAR-T cells.

[0473] Figure 9B shows the weight changes of mice in this experiment. The results showed that the weight of mice treated with PG CAR-T cells combined with PG antibodies maintained a steady increase after treatment, with average weight increases of 18.2%, 10.5%, and 8.5% after combined treatment with 0.3 mg / kg, 1 mg / kg, and 3 mg / kg of PG antibodies. The results indicate that PG CAR-T cells combined with PG antibodies produced a significant anti-tumor effect without inducing significant toxicity.

[0474] (9-2) Detection of CAR-T cells in mice: The method is the same as Example 8-2.

[0475] Figure 9C shows the expansion of PG CAR-T cells in mice in the experiment of Example 9-1. The results showed that when only PG CAR-T cells were administered, they began to proliferate in the mice one week after being infused back into the body, expanded to 919 cells / 100 μL of peripheral blood after two weeks, and rapidly decreased to 204 cells / 100 μL of peripheral blood after three weeks; when PG CAR-T cells were used in combination with different doses of PG antibodies of 0.3 mg / kg, 1 mg / kg and 3 mg / kg, the peak proliferation level of PG CAR-T cells in vivo reached 4380 cells / 100 μL of peripheral blood, 8049 cells / 100 μL of peripheral blood and 3347 cells / 100 μL of peripheral blood after two weeks, and still maintained at a high level after three weeks, which were 2475 cells / 100 μL of peripheral blood, 4121 cells / 100 μL of peripheral blood and 1969 cells / 100 μL of peripheral blood, respectively, which were much higher than the group not given antibodies in the same period. In addition, traditional Blue21CAR-T cells used as a positive control also expanded to a peak level (76,836 cells / 100 μL peripheral blood) 2 weeks after being infused back into mice, and still maintained a high level (36,328 cells / 100 μL peripheral blood) 3 weeks later.

[0476] Example 10: Anti-tumor effects of different doses of PG CAR-T cells combined with PG antibodies in vivo

[0477] (10-1) Mouse tumor inoculation and treatment

[0478] Resuspend H929 cells in 1× PBS to prepare a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right side of their backs and injected subcutaneously with H929 cell suspension at a volume of 0.2 mL per mouse, i.e., an inoculum of 1×10 6 cells / mouse. 9 days after tumor cell inoculation, the tumor volume of mice ranged from 59.50 to 105.82 mm 3 The mice were divided into 7 groups, namely vehicle group, PG Ab group, PG CAR-T group, PG Ab+PG CAR-T group, 10×10 6 Group, PG Ab+PG CAR-T, 1×10 6 Cell group, PG Ab+PG CAR-T, 0.1×10 6 Cell groups and PG Ab+PG CAR-T, 0.01×10 6The cells were divided into groups, with 7 mice in each group. The antibody concentration was 0.3 mg / mL. After grouping, the antibody was administered on the 9th day. The volume of the antibody was 10 mL / kg per mouse. The administration frequency was once a week and the administration method was intraperitoneal injection. The CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR + The cells are 50×10 6 The cell suspension was prepared by 10-fold serial dilution to prepare 5×10 6 , 0.5×10 6 and 0.05×10 6 Cell suspensions of 100 cells / mL were prepared and injected into the tail vein at a rate of 0.2 mL per mouse on day 9. The body weight, maximum longitudinal axis (L), and maximum width axis (W) of the tumor tissue were monitored twice a week.

[0479] Figure 10A shows the therapeutic effect of PG antibody combined with different doses of PG CAR-T cells in immunodeficient tumor-bearing mice inoculated subcutaneously with human H929 tumor cells. The results showed that when a very low dose of 0.01×10 6 In the case of CAR-T cells, CAR-T cells produced an anti-tumor effect similar to that of PG antibody alone, with TGIs of 49% and 50%, respectively. Increasing the CAR-T cell dose to 0.1×10 6 , 1×10 6 , 10×10 6 The anti-tumor effect induced by PG CAR-T cells was significantly increased, with TGIs of 91%, 104%, and 103%, respectively. CAR-T cell administration alone did not show an anti-tumor effect.

[0480] (10-2) In vivo CAR-T cell detection: The method is the same as Example 8-2.

[0481] Figure 10B shows the expansion of PG CAR-T cells in mice in the experiment of Example 10-1. The results showed that after CAR-T cells were infused back into mice, they began to expand under the induction of PG antibodies in one week, reached a peak level after two weeks, and remained at a high level after three weeks. In addition, when combined with PG antibodies, the expansion of CAR-T cells in vivo depended on the CAR-T cell dose. Mice in the higher CAR-T dose group had a higher level of CAR-T cell expansion, and 0.01×10 6 , 0.1×10 6 , 1×10 6 , 10×10 6 The peak expansion levels of the CAR-T cell dose groups were 6 cells / 100 μL peripheral blood, 338 cells / 100 μL peripheral blood, 3640 cells / 100 μL peripheral blood, and 12895 cells / 100 μL peripheral blood, respectively.

[0482] Example 11: Study on the in vivo anti-tumor effect of PG CAR-T cells combined with PG antibodies at different dosing frequencies

[0483] (11-1) Mouse tumor inoculation and treatment

[0484] Resuspend H929 cells in 1× PBS to prepare a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right side of their backs and subcutaneously injected with H929 cell suspension at a volume of 0.2 mL per mouse, i.e., an inoculum size of 1×10 6 cells / mouse. 7 days after tumor cell inoculation, the tumor volume of mice ranged from 51.25 to 94.97 mm 3 The mice were divided into 7 groups, namely vehicle group, PG CAR-T group, PG Ab+PG CAR-T, Q3 / 4×2 group, PG Ab+PG CAR-T, QW×4 group, PG Ab+PG CAR-T, Q2W×2 group, PG Ab+PG CAR-T, Q3W×2 group and traditional CAR-T group, with 7 mice in each group. PG Ab antibody was prepared at a concentration of 0.1 mg / mL. After grouping, the antibody was administered at a volume of 10 mL / kg per mouse by intraperitoneal injection. The CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR + Cells 10×10 6 The cells were suspended in 100 μg / mL of the suspension and injected into the tail vein at a volume of 0.2 mL per mouse. The body weight, maximum longitudinal axis (L) and maximum width axis (W) of the tumor tissue were monitored twice a week.

[0485] Figure 11A shows the dosing frequency of the PG antibody in the experiment of Example 11-1. Q3-4D × 2: PG antibody was administered twice in the first week of a 4-week cycle, with an interval of 3-4 days; Q3W × 2: PG antibody was administered twice, with a dosing frequency of 3 weeks; Q2W × 2: PG antibody was administered twice, with a dosing frequency of 2 weeks; QW × 4: PG antibody was administered 4 times, with a dosing frequency of 1 week.

[0486] Figure 11B shows the therapeutic effect of different dosing frequencies of PG antibody when combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells. The results showed that different dosing frequencies of PG antibody when combined with PG CAR-T cells could induce significant anti-tumor effects of PG CAR-T cells, and increasing the dosing frequency of PG antibody significantly increased the anti-tumor effect induced by PG CAR-T cells. The anti-tumor effect induced by CAR-T cells in the QW×4 group was the most significant, showing the same anti-tumor effect as traditional Blue21 CAR-T cells.

[0487] (11-2) In vivo CAR-T cell detection: The method is the same as Example 8-2.

[0488] Figure 11C shows the expansion of PG CAR-T cells in mice in the experiment of Example 11-1. The results showed that when PG CAR-T cells were used in combination, the CAR-T cell expansion kinetics were similar under different PG antibody administration frequencies. CAR-T cells began to expand in the mice one week after infusion, reached peak levels after two weeks, and decreased to baseline levels after three weeks. In addition, traditional Blue21 CAR-T cells also expanded in the mice two weeks after infusion and reached peak levels, and remained at high levels after three weeks.

[0489] Example 12: Study on the anti-systemic tumor effect of PG CAR-T cells combined with different doses of PG antibodies in vivo

[0490] (12-1) Mouse tumor inoculation and treatment

[0491] First, H929-luc cells were prepared. Specifically, H929 cells (purchased from Nanjing Kebai Biotechnology Co., Ltd.) were used to package a lentivirus containing the GFP-luciferase gene. The resulting lentivirus was then used to infect H929 cells. Subsequently, flow cytometry sorting was performed to obtain an H929-luc cell line that dually expressed GFP and luciferase.

[0492] Then, H929-luc cells were resuspended in 1× PBS to prepare a cell concentration of 25×10 6 NOG mice (aged 4-6 weeks, weighing 15-17g, female) were injected with H929-luc cell suspension via the tail vein at a volume of 0.2mL / mouse. Fourteen days after tumor cell inoculation, the substrate D-Luciferin (15mg / mL) was injected intraperitoneally at a volume of 10mL / kg / mouse. Ten minutes after substrate injection, IVIS spectrum imaging was used for analysis. The fluorescence signal was measured at 1.17×10 7 ~1.43×10 8 The mice with photons / sec were divided into 7 groups, namely vehicle group, PG Ab, 0.3 mg / kg group, PG Ab, 3 mg / kg group, PG CAR-T group, PG Ab+PG CAR-T, 0.3 mg / kg+2×10 6 Group, PG Ab+PG CAR-T, 3mg / kg+2×10 6The CAR-T cells prepared by donor 4 were resuspended in 1×PBS to prepare CAR-T cells. + Cells 10×10 6 On the 7th day, 0.2 mL of cell suspension was injected into the tail vein of each mouse.

[0493] Figure 12A shows fluorescence images of the therapeutic effects of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice inoculated with human H929-luc tumor cells via the tail vein. The results showed that the PG antibody combined with PG CAR-T cells also produced a significant anti-tumor effect in a systemic tumor model. On day 18, the fluorescence distribution and fluorescence intensity of mice in the PG antibody 0.3 mg / kg combined with PG CAR-T cell group were significantly reduced compared with the control group. At the same time, mice in the PG antibody 3 mg / kg combined with PG CAR-T cell group showed no obvious fluorescence signal, while the traditional Blue21 CAR-T treatment group still had a large amount of fluorescence distribution, indicating that the PG CAR-T cell group induced an anti-tumor effect faster than the Blue21 CAR-T group. The PG antibody 3 mg / kg combined with PG CAR-T cell group showed no obvious fluorescence signal until day 56. By day 63, some mice's tumors showed slight fluorescence signal. At this time, more than half of the mice in the Blue21 CAR-T treatment group had a significant recurrence of tumors and metastasis to the peritoneal cavity, indicating that the combination of PG CAR-T cells and PG antibody produces a more sustained anti-tumor effect.

[0494] Figure 12B shows the therapeutic effect of different doses of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice inoculated with human H929-luc tumor cells in the tail vein. The results showed that when PG antibody was administered at 0.3 mg / kg, PG CAR-T cells produced a certain anti-tumor effect. When the PG antibody dose was increased to 3 mg / kg, the anti-tumor effect induced by PG CAR-T cells increased significantly, and the anti-tumor effect was maintained for a longer period of time. After stopping the administration of PG antibody, tumor growth began to recur about 4 weeks later, while the tumor recurred faster after the administration of traditional Blue21 CAR-T with the same cell dose, indicating that PG CAR-T cells have a more lasting anti-tumor effect than traditional Blue21 CAR-T. The PG CAR-T cell group and the PG antibody group did not show a significant anti-tumor effect.

[0495] Figure 12C shows the changes in mouse body weight in the above experiment. The results showed that the weight of mice in each treatment group increased steadily during treatment, indicating that different doses of PG antibody combined with PG CAR-T cells did not induce significant toxicity in the hematological tumor model.

[0496] Example 13: In vivo toxicology study of PG CAR-T cells combined with PG antibodies

[0497] (13-1) Mouse tumor inoculation and treatment

[0498] Resuspend H929 cells in 1× PBS to prepare a cell concentration of 5×10 6 NOG mice (aged 4-6 weeks, weighing 15-17 g, female) were shaved on the right side of their backs and injected subcutaneously with 5×10 6 The H929 cell suspension was injected at a volume of 0.2 mL per mouse. Six days after tumor cell inoculation, the mice were treated with a tumor volume ranging from 38.49 to 104.77 mm 3 The mice were divided into 8 groups, as shown in Table 11, including vehicle group without tumor, PG Ab+PG CAR-T, 10 mg / kg+10×10 6 group; and the vehicle group, PG CAR-T group, PG Ab group, PG Ab+PG CAR-T group, 10 mg / kg+10×10 6 Group, PG Ab+PG CAR-T, 3 mg / kg+10×10 6 Group and PG Ab+PG CAR-T, 3mg / kg+1×10 6 Groups, each with 24 mice. Antibodies were prepared at concentrations of 1 mg / mL and 0.3 mg / mL, respectively. After grouping, antibodies were administered, with a volume of 10 mL / kg per mouse, once a week for 3 times, and intraperitoneal injection. One day after the first antibody administration, CAR-T cells prepared by donor 4 were resuspended in 1× PBS, and CAR + Cells 50×10 6 / mL and 5×10 6 Cell suspension was prepared using a 0.2 mL / mouse cell suspension via tail vein injection. Mouse body weight and tumor tissue maximum longitudinal axis (L) and maximum width (W) were monitored twice weekly. Peripheral blood samples were collected for hematological and biochemical analysis before the first antibody administration, after CAR-T cell infusion, before the third antibody administration, and at the end of the experiment. Four mice were included in each group.

[0499] Table 11 Treatment and dosage of each group

[0500] Figure 13A shows the therapeutic effect of PG antibody combined with PG CAR-T cells in immunodeficient tumor-bearing mice subcutaneously inoculated with human H929 tumor cells. The results showed that the PG antibody combined with PG CAR-T cell treatment groups all produced significant anti-tumor effects, while the anti-tumor effect of mice treated with only PG antibody was weak, and the administration of PG CAR-T alone did not produce an anti-tumor effect.

[0501] Figure 13B shows the changes in mouse body weight during this experiment. The results showed that the weight of mice in the tumor-bearing and non-tumor-bearing groups increased steadily during treatment, and there was no significant change in weight compared with the control mice, indicating that different doses of PG antibody combined with different doses of PG CAR-T cells did not induce obvious toxic reactions.

[0502] Figures 13C and 13D show the hematological and biochemical test results of mice in the above experiment. The results showed that during the treatment period, the hematological and biochemical parameters of mice in the tumor-bearing and non-tumor-bearing groups did not change significantly compared with the control mice, indicating that the PG antibody combined with PG CAR-T cell therapy did not produce toxic reactions.

[0503] Example 14: Clinical Study

[0504] 1. Investigational drugs and other drugs:

[0505] The active components of the test drug described in this example are: P329G BCMA antibody (ADI-38497 PG antibody, which comprises the heavy chain variable region shown in SEQ ID NO: 2 and the heavy chain constant region shown in SEQ ID NO: 5, as well as the light chain variable region shown in SEQ ID NO: 3 and the light chain constant region shown in SEQ ID NO: 6) and P329G CAR-T cells (CAR-T cells obtained by transforming the patient's autologous PBMC cells).

[0506] The formulation of P329G BCMA antibody is 20.0mg / ml P329G BCMA antibody, 0.76mg / ml histidine,

[0507] 1.08 mg / ml histidine hydrochloride, 50.00 mg / ml sorbitol, 0.20 mg / ml polysorbate 80, pH 6.0; P329G BCMA antibody specification: 60 mg (3 mL) / vial.

[0508] Specifications of P329G CAR-T cells: Each bag contains 90-140×10 cells dissolved in 5%-7.5% DMSO cryoprotectant. 6 CAR-positive cells against the P329G Fc fragment; P329G CAR-T cells are produced by Innovent Biologics (Suzhou) Co., Ltd.

[0509] Hereinafter, the drug combination containing ADI-38497 PG antibody and P329G CAR-T cells will be referred to as BCMA-CAR-PG.

[0510] 2. Inclusion / Exclusion Criteria

[0511] Inclusion criteria

[0512] 1) 18 years old and above, regardless of gender.

[0513] 2) Applicants must have documentation of a primary diagnosis of multiple myeloma based on the International Myeloma Working Group (IMWG) diagnostic criteria for multiple myeloma.

[0514] 3) After at least three anti-myeloma treatment regimens (previous treatment included proteasome inhibitors and immunomodulators), including continuous induction chemotherapy, stem cell transplantation and maintenance therapy, if there is no disease progression during treatment, it is considered as one treatment regimen; disease progression with examination data (according to IMWG criteria) occurred during or within 12 months after the most recent anti-myeloma treatment.

[0515] 4) The presence of measurable lesions at screening as determined by any of the following criteria:

[0516] ① The proportion of monoclonal plasma cells is ≥5% by bone marrow cytology, bone marrow biopsy or flow cytometry;

[0517] ② Serum monoclonal protein (M-protein) level ≥ 0.5 g / dL;

[0518] ③ Urine M-protein level ≥200 mg / 24 hours;

[0519] ④ Light chain multiple myeloma with no measurable lesions in serum or urine: serum immunoglobulin free light chains ≥ 10 mg / dL and abnormal serum immunoglobulin κ / λ free light chain ratio.

[0520] 5) ECOG performance score is 0 or 1.

[0521] 6) Expected survival time ≥ 12 weeks.

[0522] Exclusion criteria:

[0523] 1) Patients with graft-versus-host disease (GVHD) or those who need to use immunosuppressants.

[0524] 2) Patients who had received autologous hematopoietic stem cell transplantation (ASCT) within 12 weeks before PBMC collection or had previously received allogeneic hematopoietic stem cell transplantation (allo-HSCT).

[0525] 3) No non-mobilized mononuclear cells can be collected for CAR-T cell production.

[0526] 4) Previous anti-tumor treatment:

[0527] ① Received cytotoxic or proteasome inhibitor treatment within 14 days before mononuclear cells can be collected, or;

[0528] ② receiving systemic steroid treatment within 7 days before mononuclear cells can be collected, or;

[0529] ③ Use of monoclonal antibodies to treat multiple myeloma within 21 days before mononuclear cells can be collected, or;

[0530] ④Received immunomodulatory therapy within 7 days before mononuclear cells can be collected, or;

[0531] ⑤ Received targeted therapy, epigenetic therapy, or used invasive experimental medical devices within 14 days before mononuclear cells can be collected, or;

[0532] ⑥Received radiotherapy within 14 days before mononuclear cells can be collected. However, if the radiation field covers ≤5% of the bone marrow reserve, the subject is eligible to participate in the study regardless of the end date of radiotherapy, or;

[0533] ⑦ Undergo leukocyte apheresis within 7 days before mononuclear cells can be collected.

[0534] 5) Subjects who are determined by the investigator to require long-term use of systemic steroids during treatment (except for inhaled or topical use, and with a dose of <10 mg / day).

[0535] 6) Patients with a history of hypertension that cannot be controlled by drug treatment (blood pressure ≥ 140 / 90 mmHg).

[0536] 7) Severe heart disease: including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), and severe arrhythmia.

[0537] 8) Systemic diseases judged by the investigator to be unstable: including but not limited to severe liver, kidney or metabolic diseases requiring drug treatment.

[0538] 9) Patients with malignant tumors other than multiple myeloma within 5 years before screening, except for fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, and breast ductal carcinoma in situ after radical surgery.

[0539] 10) Those with a history of solid organ transplantation.

[0540] 11) Patients with a history of T-cell-mediated autoimmune diseases (such as type 1 diabetes, multiple sclerosis, rheumatoid arthritis, and systemic lupus erythematosus). If the researcher determines that the patient may have the above-mentioned T-cell-mediated autoimmune disease indications before enrollment, relevant disease testing is required to exclude the above-mentioned autoimmune diseases before enrollment.

[0541] 12) Patients suspected of or with symptoms of central nervous system invasion by plasma cell tumors.

[0542] 13) Stroke or seizure occurred within 6 months before signing the ICF.

[0543] 14) Suffering from plasma cell leukemia at the time of screening (according to domestic standards, the plasma cell percentage in peripheral blood leukocyte classification is greater than 20% or the absolute value of plasma cells is ≥2.0×10 9 / L), Waldenstrom's macroglobulinemia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal proteinopathy, and skin changes), or primary systemic light-chain amyloidosis (AL).

[0544] 15) Patients who have received live attenuated vaccines within 4 weeks before mononuclear cell collection.

[0545] 16) Major surgery has been performed within 2 weeks before mononuclear cell collection, or surgery is planned within 2 weeks after apheresis or the first administration of study treatment (Note: Subjects who plan to undergo surgery under local anesthesia can participate in this study).

[0546] 17) Participating in other interventional clinical studies when signing the ICF.

[0547] 18) Active infection or uncontrolled infection requiring systemic treatment (except CTCAE grade 1 genitourinary system infection and upper respiratory tract infection) within 7 days before mononuclear cell collection.

[0548] 3. Dosage method and process

[0549] The enrolled subjects will undergo peripheral blood mononuclear cell (PBMC) apheresis (D-33 to D-26 (-33 days to -26 days)), and then use the subjects' own T cells to prepare P329G CAR-T cell preparations (hereinafter referred to as P329G CAR-T cells). After successful preparation of P329G CAR-T cells, subjects will first receive a lymphoproliferative conditioning regimen of cyclophosphamide and fludarabine (D-5 to D-3 (-5 days to -3 days)); after two days of rest after the completion of conditioning, they will receive a single infusion of P329G BCMA antibody (also known as ADI-38497 PG antibody) (D1); within 1 to 2 hours after the completion of P329G BCMA antibody infusion or on the next day (D2), they will receive P329G CAR-T cell infusion; thereafter, starting from the day of P329GBCMA antibody infusion, ADI-38497 PG will be periodically infused every 21 days (the first cycle (days 1-21) includes both QW*3 dosing and Q3W dosing, and Q3W dosing is used in the second cycle and thereafter) until disease progression, intolerable toxicity, withdrawal of informed consent by the subject, or other reasons for discontinuation of study treatment (whichever occurs first).

[0550] The relevant dosage regimens are shown in the following table:

[0551] Dose escalation phase:

[0552] In the dose escalation phase, the classic "3+3" dose escalation method was used. ADI-38497 PG antibody had four dose groups: 0.1mg / kg, 0.3mg / kg, 1mg / kg, and 3mg / kg; P329G CAR-T cells had two dose groups: 2*10 6 pcs / kg and 5*10 6 First, the P329G CAR-T cell dose was fixed to fully explore the optimal dose of ADI-38497 PG, with a starting dose of 2*10 6 P329G CAR-T cells / kg and 0.1mg / kg ADI-38497 PG. If the initial dose is not tolerated, consider reducing the cell dose to 0.75*10 6 The DLT observation window is 21 days after the first dose of ADI-38497 PG antibody. If the above BCMA-CAR-PG dose does not reach the maximum tolerated dose (MTD), the ADI-38497 PG antibody dose will be fixed and the P329G CAR-T cell dose will be increased to 5*10 6 / kg continue to explore.

[0553] In the dose-escalation phase, the possible dose groups for BCMA-CAR-PG administration are as follows:

[0554] Dose group 1: 0.1mg / kg ADI-38497 PG antibody + 2*10 6 P329G CAR-T cells / kg (n=3-6);

[0555] Dose group 2: 0.3mg / kg ADI-38497 PG antibody + 2*10 6 P329G CAR-T cells / kg (n=3-6);

[0556] Dose group 3: 1mg / kg ADI-38497 PG antibody + 2*10 6 P329G CAR-T cells / kg (n=3-6);

[0557] Dose group 4: 3mg / kg ADI-38497 PG antibody + 2*10 6 P329G CAR-T cells / kg (n=3-6);

[0558] Dose group 5: 3mg / kg ADI-38497 PG antibody + 5*10 6 P329G CAR-T cells / kg (n=3-6)

[0559] Exploratory dose group: e.g. 1mg / kg ADI-38497 PG antibody + 5*10 6 P329G CAR-T cells / kg (n=3-6) or an exploratory dose group selected after full discussion between the investigator and the sponsor based on previous observation data.

[0560] The relevant dosages of P329G CAR-T cells and P329G BCMA antibody are shown in the following table:

[0561] 4. Experimental Results

[0562] The meanings of the experimental results are as follows

[0563] 1. Efficacy:

[0564] The C-BCMA-CAR-PG-01 and C-BCMA-CAR-PG-02 regimens are summarized as follows:

[0565] C-BCMA-CAR-PG-Y001: A total of 6 subjects were enrolled, including 3 in the 0.3 mg / kg dose group and 3 in the 1 mg / kg dose group. According to investigator assessment, 3 subjects achieved a PR as their best tumor assessment. In the 0.3 mg / kg dose group, one subject achieved a PR as their best tumor assessment, which persisted for 7 months before disease progression. In the 1 mg / kg dose group, two subjects achieved a PR as their best tumor assessment, one of which persisted for 2 months before disease progression (as shown in Figure 14).

[0566] C-BCMA-CAR-PG-Y002: A total of five subjects were enrolled, including one in the 0.1 mg / kg dose group, three in the 0.3 mg / kg dose group, and one in the 1 mg / kg dose group. Investigator-assessed, one subject in the 0.1 mg / kg dose group achieved a VGPR (very good partial response) as a best tumor assessment three months after infusion and maintained this VGPR at the most recent six-month visit. One subject in the 0.3 mg / kg dose group also achieved a PR as a best tumor assessment at the most recent three-month visit (as shown in Figure 15).

[0567] 2. Cell PK:

[0568] C-BCMA-CAR-PG-01: The median (range) time to peak cell expansion (Tmax) of the 0.3 mg / kg (N=3) and 1 mg / kg (N=3) dose groups was 20 (14-33.8) days and 13.8 (9.71-26.8) days, respectively; the geometric mean (coefficient of variation) of peak cell expansion (Cmax) was 1.01*10^4 (148.6%) and 10.3*10^4 (50.6%) copies / μg DNA, respectively; the geometric mean (coefficient of variation) of cell AUC0-21d was 4.24*10^4 (145%) and 17.4*10^4 (89.4%) day*copies / μg DNA, respectively.

[0569] C-BCMA-CAR-PG-02: The median (range) time to peak cell expansion (Tmax) for the 0.1 mg / kg (N=1), 0.3 mg / kg (N=3) and 1 mg / kg (N=1) dose groups was 20.9 days, 16 (12.9-17.9) days and 20.9 days, respectively; the geometric mean (coefficient of variation) of peak cell expansion (Cmax) was 7*10^4 (NaN), 3.27*10^4 (85.1%) and 1.66*10^4 (NaN) copies / μg DNA, respectively; the geometric mean (coefficient of variation) of cell AUC0-21d was 47.1*10^4 (NaN), 19.1*10^4 (69.4%) and NaN (NaN) day*copies / μg DNA, respectively.

[0570] 3. Antibody PK

[0571] C-BCMA-CAR-PG-01: The geometric mean (coefficient of variation) of peak drug concentration (Cmax) in the 0.3 mg / kg (N=3) and 1 mg / kg (N=3) dose groups were 4.88 (97.2%) and 9.89 (71.9%) μg / mL, respectively. The geometric mean (coefficient of variation) of the area under the plasma concentration-time curve (AUC0-last) was 200 (132.4) and 117.6 (127%) μg·h / mL, respectively. The geometric mean (coefficient of variation) of clearance (CL) was NaN (NaN) and 0.000671 (104.9%) L / h / kg, respectively. The geometric mean (coefficient of variation) of half-life (t1 / 2) was NaN (NaN) and 88.9 (133.6%) h, respectively. Within the dose range of 0.3 to 1 mg / kg, target-mediated drug elimination dominated, and ADI-38497 PG antibody was rapidly cleared.

[0572] C-BCMA-CAR-PG-02: The geometric mean (coefficient of variation) of peak drug concentration (Cmax) for the 0.1 mg / kg (N=1), 0.3 mg / kg (N=3), and 1 mg / kg (N=1) dose groups were 1.95 (NaN), 3.99 (58.1%), and 7.83 (NaN) μg / mL, respectively. The geometric mean (coefficient of variation) of the area under the plasma concentration-time curve (AUC0-last) was 20.2 (NaN), 23.8 (82.4%), and 30 (NaN) μg·h / mL, respectively. The geometric mean (coefficient of variation) of clearance (CL) was 0.00439 (NaN), NaN (NaN), and NaN (NaN) L / h / kg, respectively. The geometric mean (coefficient of variation) of half-life (t1 / 2) was 9.79 (NaN), NaN (NaN), and NaN (NaN) h, respectively. Within the dose range of 0.1 to 1 mg / kg, target-mediated drug elimination dominated, and ADI-38497 PG antibody was rapidly cleared.

[0573] At the current dose, the target-mediated drug elimination effect is obvious. Based on this, it is recommended that a QW dosing frequency of antibodies in the first cycle will be more conducive to maintaining effective antibody concentrations.

[0574] 4. Safety data:

[0575] In the C-BCMA-CAR-PG-01 study, 5 subjects experienced treatment-related adverse events (TRAEs). The most common TRAEs were decreased neutrophil count (5 cases, 83.3%), decreased lymphocyte count (5 cases, 83.3%), decreased white blood cell count (5 cases, 83.3%), and decreased platelet count (5 cases, 83.3%).

[0576] In the C-BCMA-CAR-PG-02 study, 5 subjects experienced TRAEs, with the most common TRAEs being decreased neutrophil count (5 patients, 100%), decreased white blood cell count (5 patients, 100%), decreased platelet count (5 patients, 100%), and anemia (5 patients, 100%).

[0577] Based on the above non-clinical study results, mechanism of action, previous clinical research experience of similar drugs and preliminary clinical safety data, it is proved that the product of the present invention has achieved relatively good safety effect:

[0578] (1) CRS: As of the data cutoff date, in both studies, 5 of 11 subjects developed CRS of varying degrees, with a CRS incidence rate of 45.5%, which is lower than that of existing BCMA-CART products. Under the current circumstances, the CRS that have occurred is relatively controllable, and all subjects have improved or been cured after treatment;

[0579] (2) ICANS (Immune Effector Cell-Associated Neurotoxicity Syndrome): As of the data cutoff date, no neurotoxic events were observed in either study. Overall, BCMA-CAR-PG has a good safety and tolerability profile, with lower incidences of CRS and ICANS than existing products.

[0580] (3)(3) Clinical results show that CART cells in the bodies of subjects who have been administered this product can be maintained for a longer period of time, which has certain guiding significance for the clinical treatment effect.

[0581] Example 15. Typical Case

[0582] Case 1: C-BCMA-CAR-PG-02 patient, a 46-year-old female, had IgG-κ multiple myeloma, DS stage III, no extramedullary lesions, and had previously received seven chemotherapy regimens, including proteasome inhibitors, immunomodulators, and glucocorticoids. The baseline bone marrow plasma cell ratio was 31%. The patient signed an informed consent form on June 16, 2022, and received 0.1 mg / kg of the antibody and 2 x 10 cells. 6 / kg dose group. Mononuclear cells were collected on June 27, 2022, and the first antibody and cell transfusion was performed on August 9, 2022. The second and third antibody administrations of the first cycle were performed on August 16 and 23, 2022, respectively; the second and third antibody administrations were performed on August 30, 2022 and September 20, 2022; the fourth and fifth cycles were missed due to the epidemic; the sixth cycle was performed on November 28, 2022; the seventh and eighth cycles were missed due to the epidemic; the ninth and tenth cycles were performed on February 3, 2023 and February 23, 2022. The patient's tumor evaluation result at one month was PR, and the tumor evaluation results at three and six months were VGPR, and the patient was in sustained remission. The patient's cell PK results are shown in Figure 18 below. The amplification peak was reached at D15, and the level was 10 5 The patient's CAR-T persistence is good, and CAR-T can still be detected half a year after the infusion, with a level of 10 3Around 10 days after cell infusion, the patient's cytokine levels, including IL-6, IL-10, IL-2R, and TNF-α, peaked, then declined to normal around 15 days later. The patient developed grade 1 CRS on day 9 after infusion, which lasted for 6 days before resolving.

[0583] Case 2: C-BCMA-CAR-PG-01 patient, male, 43 years old, with kappa light chain multiple myeloma, DS stage III-A, and concomitant extramedullary lesions. Baseline bone marrow plasma cell percentage was 0.5%. The patient signed the informed consent form on April 27, 2022, and received 0.3 mg / kg of antibody and 2 x 10 cells. 6 / kg dose group. Mononuclear cells were collected on May 11, 2022, the first antibody infusion was performed on June 20, 2022, and the cells were reinfused on June 21, 2022. The subsequent antibodies were administered once every three weeks, and a total of 9 cycles of antibody administration were completed. The tumor evaluation result of the patient was SD 3 weeks after administration, and the efficacy evaluation was PR 9 weeks after administration. The disease progressed after PR lasted for 7 months. The patient's cell PK results are shown in Figure 20 below. The amplification peak was reached on D15, and the level was 10 5 About 10 days after cell transfusion, the patient's cytokines, including IL-6, IL-10, and TNF-α, showed a significant peak, and then decreased to the normal range around 15 days later (Figure 21).

[0584] While the exemplary embodiments of the present invention have been described above, it should be understood by those skilled in the art that these disclosures are merely exemplary and that various other substitutions, adaptations, and modifications may be made within the scope of the present invention. Therefore, the present invention is not limited to the specific embodiments listed herein.

[0585] Exemplary sequences

Claims

1. A method of treating multiple myeloma in an individual, comprising administering to the individual a drug combination comprising (i) T cells expressing a molecular switch-regulated CAR polypeptide, i.e., CAR-T cells, wherein the CAR polypeptide comprises a humanized anti-P329G mutant scFv sequence that is capable of specifically binding to an antibody Fc domain comprising a P329G mutation, but is unable to specifically bind to an unmutated parent antibody Fc domain; (ii) an antibody or antigen-binding fragment that specifically binds to a BCMA molecule comprising a P329G mutation, wherein the P329G mutant antibody comprises a mutant Fc domain, wherein the amino acid at position P329 according to EU numbering is mutated to glycine (G); Among them, about 0.5×10 6 cells / kg body weight - approximately 5×10 6 The CAR-T cells are administered at a dosage unit of about 0.1-3 mg / kg body weight, and the antibody or antigen-binding fragment is administered in a dosage unit of about 0.1-3 mg / kg.

2. The method of claim 1, comprising administering CAR-T cells and the antibody or antigen-binding fragment thereof in a dosage regimen as follows: In the first cycle, the antibody or antigen-binding fragment thereof is administered on the first day, and the CAR-T cells are administered at an interval of 1-5 hours or the CAR-T cells are administered on the second day (e.g., at an interval of 24 hours); and the antibody or antigen-binding fragment thereof is administered every 1 week (QW), 2 weeks (Q2W), or every 3 weeks (Q3W) starting from the first day; and Optionally, the second cycle to the nth cycle: in each cycle, the antibody or antigen-binding fragment thereof is administered every three weeks (Q3W), wherein n=2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 or more.

3. The method of claim 2, wherein each administration cycle is 21 days or 28 days.

4. The method of any one of claims 1 to 3, wherein the CAR-T cells are present at approximately 0.75×10 6 cells / kg body weight, 1×10 6 cells / kg body weight, 1.5×10 6 cells / kg body weight, 2×10 6 cells / kg body weight, 2.5×10 6 cells / kg body weight, 3×10 6 cells / kg body weight, 3.5×10 6 cells / kg body weight, 4×10 6 cells / kg body weight, 4.5×10 6 cells / kg body weight, 5×10 6 The subject is administered 10 cells / kg body weight, preferably in a single administration.

5. The method of any one of claims 1-4, wherein the antibody or antigen-binding fragment thereof is administered in a single dose unit of about 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg.

6. The method of any one of claims 1-5, wherein the CAR-T cells and the antibody or antigen-binding fragment thereof are administered intravenously.

7. The method of any one of claims 1-6, wherein the individual undergoes a lymphodepletion regimen prior to administration of the antibody or antigen-binding fragment thereof.

8. The method of claim 7, wherein the lymphodepleting regimen comprises administration of cyclophosphamide and fludarabine.

9. The method of claim 7 or 8, wherein the lymphodepletion regimen is initiated between 3-5 days prior to administration of the antibody or antigen-binding fragment thereof.

10. The method of any one of claims 7 to 9, wherein the lymphodepletion regimen lasts for about 1 to 5 days, such as about 3 days.

11. The method of any one of claims 1-10, wherein the antibody or antigen-binding fragment that specifically binds to the BCMA molecule comprising the P329G mutation comprises a heavy chain variable region and a light chain variable region, wherein The heavy chain variable region comprises CDR H1 shown by the amino acid sequence SSSYYWT (SEQ ID NO:25) according to Kabat numbering; CDR H2 shown by the amino acid sequence SISIAGSTYYNPSLKS (SEQ ID NO:26); and CDR H3 shown by the amino acid sequence DRGDQILDV (SEQ ID NO:27); the light chain variable region comprises CDR L1 shown by the amino acid sequence RASQSISRYLN (SEQ ID NO:28) according to Kabat numbering; CDR L2 shown by the amino acid sequence AASSLQS (SEQ ID NO:29); and CDR L3 shown by the amino acid sequence QQKYFDIT (SEQ ID NO:30).

12. The method of claim 11, wherein The heavy chain variable region comprises the sequence of SEQ ID NO:2, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain variable region comprises the sequence of SEQ ID NO:3, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

13. The method of claim 12, wherein The heavy chain variable region comprises or consists of the sequence of SEQ ID NO:2, and the light chain variable region comprises or consists of the sequence of SEQ ID NO:

3.

14. The method of any one of claims 11 to 13, wherein the Fc domain is selected from the Fc domain of IgG1, IgG2, IgG3 or IgG4, such as the Fc domain of IgG1.

15. The method of claim 14, wherein the Fc domain comprises the amino acid sequence of SEQ ID NO: 10, or has at least 85%, 90%, 95%, 96%, 97%, 98% or 99% sequence identity thereto and comprises a P329G mutation.

16. The method of any one of claims 1-15, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain constant region comprising the amino acid sequence shown in SEQ ID NO:5, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto and wherein the amino acid at position P329 according to EU numbering is mutated to G.

17. The method of any one of claims 1-16, wherein the antibody or antigen-binding fragment thereof comprises a light chain constant region comprising the amino acid sequence shown in SEQ ID NO:6 or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

18. The method of claim 17, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain constant region and a light chain constant region, wherein the heavy chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO:5, and the light chain constant region comprises or consists of the amino acid sequence shown in SEQ ID NO:

6.

19. The method of any one of claims 1-18, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain comprising the amino acid sequence shown in SEQ ID NO:34, or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto and wherein the amino acid at position P329 according to EU numbering is mutated to G.

20. The method of any one of claims 1-19, wherein the antibody or antigen-binding fragment thereof comprises a light chain comprising the amino acid sequence shown in SEQ ID NO:35, or a sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

21. The method of claim 20, wherein the antibody or antigen-binding fragment thereof comprises a heavy chain and a light chain, wherein the heavy chain comprises or consists of the amino acid sequence shown in SEQ ID NO:34, and the light chain comprises or consists of the amino acid sequence shown in SEQ ID NO:

35.

22. The method of any one of claims 1-21, wherein the molecular switch-regulated CAR polypeptide comprises a humanized anti-P329G mutant scFv sequence, wherein the scFv sequence comprises (i) a heavy chain variable region comprising a (a) CDR H1 represented by the amino acid sequence RYWMN (SEQ ID NO: 19); (b) CDR H2 represented by the amino acid sequence EITPDSSTINYAPSLKG (SEQ ID NO: 20); and (c) CDR H3 represented by the amino acid sequence PYDYGAWFAS (SEQ ID NO: 21); and (ii) a light chain variable region comprising a (d) CDR L1 represented by the amino acid sequence RSSTGAVTTSNYAN (SEQ ID NO: 22); (e) CDR L2 represented by the amino acid sequence GTNCRAP (SEQ ID NO: 23); and (f) CDR L3 represented by the amino acid sequence ALWYSNHWV (SEQ ID NO: 24).

23. The method of claim 22, wherein the scFv comprises a heavy chain variable region and a light chain variable region, wherein the heavy chain variable region comprises the sequence of SEQ ID NO: 12, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and the light chain variable region comprises the sequence of SEQ ID NO: 13, or a sequence at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto.

24. The method of claim 23, wherein the heavy chain variable region comprises or consists of the sequence of SEQ ID NO: 12, and the light chain variable region comprises or consists of the sequence of SEQ ID NO:

13.

25. The method of any one of claims 1-24, wherein the CAR polypeptide comprises: (1) a hinge region / spacer region selected from (i)(G4S) n 、(SG4) n or G4(SG4) n A peptide linker, wherein "n" is an integer from 1 to 4, such as the sequence shown in SEQ ID NO: 14; (ii) the CD8α hinge region sequence shown in SEQ ID NO: 18 or a variant thereof having one amino acid modification; (2) a transmembrane region (TM) selected from the CD8 transmembrane domain shown in SEQ ID NO: 15 or a variant thereof having one amino acid modification; (3) a co-stimulatory signaling domain (CSD) selected from the 4-1BB co-stimulatory domain shown in SEQ ID NO: 16 or a variant thereof having one amino acid modification; (4) a stimulatory signaling domain (SSD) selected from the CD3 zeta signaling domain shown in SEQ ID NO: 17 or a variant thereof having one amino acid modification, The amino acid modification is the addition, deletion or substitution of amino acids.

26. The method of any one of claims 1-25, wherein the molecular switch-regulated CAR polypeptide further comprises a signal peptide sequence located at the N-terminus, for example, the signal peptide sequence shown in SEQ ID NO:

11.

27. The method of any one of claims 1-26, wherein the molecular switch-regulated CAR polypeptide has an amino acid sequence as shown in SEQ ID NO: 1 or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity thereto.

28. The method of any one of claims 1-27, wherein the CAR-T cell comprises a nucleic acid molecule encoding the CAR polypeptide.

29. The method of any one of claims 1-28, wherein the multiple myeloma is refractory multiple myeloma.

30. The method of any one of claims 1-28, wherein the multiple myeloma is relapsed multiple myeloma.

31. The method of any one of claims 1-28, wherein the multiple myeloma is refractory and relapsed multiple myeloma.

32. The method of any one of claims 1-31, wherein the individual has been through at least three prior therapies for multiple myeloma.

33. The method of any one of claims 1-32, wherein the individual has been treated with at least three prior therapies for multiple myeloma including treatment with a proteasome inhibitor and an immunomodulatory agent.

Citation Information

Patent Citations

  • Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

    CN106687483A

  • Anti-variant Fc-region antibodies and methods of use

    CN108350066A

  • Monoclonal antibodies against BCMA

    CN111269315A

  • Anti-BCMA humanized single-chain antibody and application

    CN111944047A

  • Chimeric antigen receptor CAR or CAR construct targeting BCMA and CD19 and application of chimeric antigen receptor CAR or CAR construct

    CN115715298A